<SEC-DOCUMENT>0001493152-24-043330.txt : 20241101
<SEC-HEADER>0001493152-24-043330.hdr.sgml : 20241101
<ACCEPTANCE-DATETIME>20241101161514
ACCESSION NUMBER:		0001493152-24-043330
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20241028
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241101
DATE AS OF CHANGE:		20241101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CONDUIT PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001896212
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				873272543
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41245
		FILM NUMBER:		241419270

	BUSINESS ADDRESS:	
		STREET 1:		4995 MURPHY CANYON ROAD, SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		(760) 471 8536

	MAIL ADDRESS:	
		STREET 1:		4995 MURPHY CANYON ROAD, SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Murphy Canyon Acquisition Corp.
		DATE OF NAME CHANGE:	20211130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CDT="http://conduitpharma.com/20241028">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_CDT_conduitpharma.com_20241028 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20241028_20241028 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001896212 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000004" name="dei:EntityCentralIndexKey">0001896212</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cdt-20241028.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-10-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-28</xbrli:startDate>
        <xbrli:endDate>2024-10-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-282024-10-28_custom_CommonStock0.0001ParValuePerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:CommonStock0.0001ParValuePerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-28</xbrli:startDate>
        <xbrli:endDate>2024-10-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-282024-10-28_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-28</xbrli:startDate>
        <xbrli:endDate>2024-10-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_909_edei--DocumentType_c20241028__20241028_zwl2xKG7Efif"><ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <b><span id="xdx_90B_edei--DocumentPeriodEndDate_c20241028__20241028_zZOqDLv1sP27"><ix:nonNumeric contextRef="AsOf2024-10-28" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">October 28, 2024</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20241028__20241028_z0qtGCq9LMYf"><ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000011" name="dei:EntityRegistrantName">Conduit
Pharmaceuticals Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20241028__20241028_z2DdSR3SrS9b"><ix:nonNumeric contextRef="AsOf2024-10-28" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityFileNumber_c20241028__20241028_zrzwtHOrS9c6"><ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000013" name="dei:EntityFileNumber">001-41245</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20241028__20241028_zyDR0cBgkiVj"><ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000014" name="dei:EntityTaxIdentificationNumber">87-3272543</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 66%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20241028__20241028_zKhfClEPJAee"><ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000015" name="dei:EntityAddressAddressLine1">4995
    Murphy Canyon Road</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20241028__20241028_zR25fNU4ZNR1"><ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 300</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressCityOrTown_c20241028__20241028_zKPhypBaoF6i"><ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000017" name="dei:EntityAddressCityOrTown">San
    Diego</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20241028__20241028_z4uZz2cYmoJ5"><ix:nonNumeric contextRef="AsOf2024-10-28" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressPostalZipCode_c20241028__20241028_ze1CHt8cF35a"><ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000019" name="dei:EntityAddressPostalZipCode">92123</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <b><span id="xdx_903_edei--CityAreaCode_c20241028__20241028_zAnkpaoIsjV3"><ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000020" name="dei:CityAreaCode">(760)</ix:nonNumeric></span> <span id="xdx_90E_edei--LocalPhoneNumber_c20241028__20241028_zpUHcdihMhNh"><ix:nonNumeric contextRef="AsOf2024-10-28" id="Fact000021" name="dei:LocalPhoneNumber">471-8536</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Not
Applicable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under
any of the following provisions (<span style="text-decoration: underline">see</span> General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--WrittenCommunications_c20241028__20241028_zuedDR8ACLd8"><ix:nonNumeric contextRef="AsOf2024-10-28" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--SolicitingMaterial_c20241028__20241028_z1si6ZIOm3b5"><ix:nonNumeric contextRef="AsOf2024-10-28" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20241028__20241028_ziywALFF8IHj"><ix:nonNumeric contextRef="AsOf2024-10-28" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20241028__20241028_znhK6pMtAih2"><ix:nonNumeric contextRef="AsOf2024-10-28" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20241028__20241028__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zRJvmSliSaw9"><ix:nonNumeric contextRef="From2024-10-282024-10-28_custom_CommonStock0.0001ParValuePerShareMember" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20241028__20241028__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zZajTVM8KDAd"><ix:nonNumeric contextRef="From2024-10-282024-10-28_custom_CommonStock0.0001ParValuePerShareMember" id="Fact000027" name="dei:TradingSymbol">CDT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20241028__20241028__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zYK4Yy7Q2vW8"><ix:nonNumeric contextRef="From2024-10-282024-10-28_custom_CommonStock0.0001ParValuePerShareMember" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20241028__20241028__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_zDMWIO11vlw4"><ix:nonNumeric contextRef="From2024-10-282024-10-28_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" id="Fact000029" name="dei:Security12bTitle">Redeemable
    Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20241028__20241028__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_z3QBXSHdrPl5"><ix:nonNumeric contextRef="From2024-10-282024-10-28_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" id="Fact000030" name="dei:TradingSymbol">CDTTW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--SecurityExchangeName_c20241028__20241028__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_zY3WoIhNKj7l"><ix:nonNumeric contextRef="From2024-10-282024-10-28_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20241028__20241028_zfWv9ElbDCfj"><ix:nonNumeric contextRef="AsOf2024-10-28" format="ixt:booleantrue" id="Fact000032" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_900_edei--EntityExTransitionPeriod_c20241028__20241028_zPp8fF6jIAT"><ix:nonNumeric contextRef="AsOf2024-10-28" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>A.G.P.
Loan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
October 29, 2024, Conduit Pharmaceuticals Inc. (the &#8220;Company&#8221;) entered into a Bridge Loan Agreement (the &#8220;Bridge Agreement&#8221;),
with A.G.P./Alliance Global Partners (&#8220;A.G.P.&#8221;), pursuant to which A.G.P. made an advance (the &#8220;Advance&#8221;) to
the Company in an amount not to exceed $600,000 (the &#8220;Commitment&#8221;). As partial consideration for the Advance, the Company
issued A.G.P. warrants (the &#8220;Warrants&#8221;) to purchase up to 2,862,596 shares of the Company&#8217;s common stock, $0.0001 par
value per share (the &#8220;Common Stock&#8221;), which is equal to 50% of the sum of the Commitment divided by the closing price of
the Company&#8217;s Common Stock on October 29, 2024, at an exercise price of $0.1048 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise of the Warrants and the issuance of the shares of Common Stock underlying the Warrants is subject to stockholder approval under
applicable rules and regulations of The Nasdaq Stock Market LLC, to the extent required by such rules and regulations. The Company has
agreed to convene a meeting of stockholders on or before the 90th day following the issuance of the Warrants to approve the issuance
of Common Stock upon exercise of the Warrants, if required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
connection with the Advance, the Company issued a promissory note (the &#8220;Bridge Note&#8221;) to A.G.P. in the original principal
amount of $600,000. The Bridge Note bears interest at a rate of 4.21% per annum and is due and payable on December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
to the Bridge Agreement, the Company and A.G.P. also agreed to amend a fee letter agreement entered into between the Company and A.G.P.,
effective September 22, 2023, suspending the provision that the Company was required to pay A.G.P. 25% of all net proceeds received from
certain transactions described therein, for the repayment of an outstanding amount owed to A.G.P., until such time as the Bridge Note
is repaid in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to providing funding pursuant to the Bridge Loan Agreement, as discussed herein, A.G.P. is currently engaged as the sales agent
in connection with the Company&#8217;s recently filed preliminary prospectus supplement relating to the Company&#8217;s at the market
offering of up to approximately $3.5 million it intends to undertake in the near term. The initial proceeds received by the Company from
its at the market offering will be first used to repay the Bridge Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Nirland
Note and Amendment to Nirland Debt Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 28, 2024, the Company issued a promissory note (the &#8220;Nirland Note&#8221;) to Nirland Limited (&#8220;Nirland&#8221;)
in the original principal amount of $600,000 in exchange for funds in such amount. The Nirland Note bears interest at a rate of 12% per
annum, is due and payable semi-annually in arrears, and matures on October 31, 2025. If an event of default under and as
defined in the Nirland Note occurs, the interest rate will be increased to 18% per annum or to the maximum rate permitted by law. In
connection with the Nirland Note, the Company has agreed to pay Nirland a 1% arrangement fee, which will be included with the principal
and interest owed under the Nirland Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As previously disclosed by the Company,
on August 6, 2024, the Company entered into a Senior Secured Promissory Note (the &#8220;Existing Note&#8221;) and a Security Agreement
(the &#8220;Security Agreement&#8221;, and collectively with the Existing Note, the &#8220;Nirland Debt Agreements&#8221;) with Nirland,
pursuant to which the Company issued and sold to Nirland the Existing Note in the original principal amount of $2,650,000, inclusive
of a $500,000 original issuance discount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On October 31, 2024, the Company and
Nirland amended the Nirland Debt Agreements (the &#8220;Debt Amendment&#8221;), whereby the Nirland Debt Agreements were amended to (i)
provide for the conversion of the Existing Note into shares of Common Stock, at Nirland&#8217;s discretion, in a multiple of any unpaid
amounts, if not otherwise previously paid, pursuant to the conversion rate contained therein, (ii) remove Nirland&#8217;s mandatory prepayment
right, and (iii) remove Nirland&#8217;s right of first refusal to participate in any future equity or debt offerings of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bridge Agreement, Bridge Note, form of Warrant, Nirland Note, and Debt Amendment are attached as Exhibits 10.1, 4.1, 4.2, 4.2,
and 4.3, respectively. The description of the terms of the Bridge Agreement, Warrants, Bridge Note, Nirland Note, and Debt
Amendment is not intended to be complete and is qualified in its entirety by reference to such exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.02 Termination of a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disclosure contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 1.02.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
disclosure contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.02 Unregistered Sales of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued the Warrants and entered into the Debt Amendment pursuant to the exemption from the registration requirements of
the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), available under Section 4(a)(2). <span style="background-color: white">The
shares of Common Stock underlying the Warrants and upon conversion of the Existing Note, as amended, have not been registered
under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from
registration under the Securities Act and any applicable state securities laws. The descriptions of the Warrants and the Existing
Note, as amended, under Item 1.01 of this Current Report on Form 8-K are incorporated by reference herein.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;9.01
- Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><div style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></p>
</div></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Bridge
    Note</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-2.htm">Form
    of Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-3.htm">Nirland
    Note</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; white-space: nowrap; text-align: center">4.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex4-4.htm">Amendment to Senior Secured Promissory
    Note and Security Agreement, dated October 31, 2024, between Nirland Limited and Conduit Pharmaceuticals Inc.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Bridge Loan Agreement, dated October 29, 2024, between A.G.P./Alliance Global Partners and Conduit Pharmaceuticals Inc.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 1, 2024</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDUIT
    PHARMACEUTICALS INC. </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Tapolczay</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    David Tapolczay</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kk1uwjAQhU/AHUZRlwjsFLpgRxGtqkKJaAXdmjApFoknGpu/I/WWtR2lsGgjS5E97/l7M3KSdJNnetIlMnw+LmfwgVVdKoewxAIZTY5eMXl5HYH/L/FLW8fKuLhtjRPyHvSeYS8dbHwhSo/a4nYEUvTvZT8dgEhH8gGyedIJ9QmZQm/ROK1KUGYLGVPNGp3iS3PDhzqToeoSUStkq8n463qiKX9DKmQKb3RUJ+K9hdlsknS68eskz0yH2qumZ4cmOGFaYuVxtnFfV0yTH6yjarTELWKlNiWuFYc27VTlu/WOfg+mZ+Rc2yB5Il4YfN8pxkXhR1CReXeU78etCDPWua9J2RuKOVYbZI+SIk2lGIt2TC0RWmQX0EPhFKhwag4Br1woiIEMgg1ooAIaOEQ6KOfH2eoR6pAhiO5ijD+avokuekIImSleqfKAGXLs7p/ot9Qu3DVeqBXDMbih9i8jRmyZP8gZwXo= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROMISSORY
NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$600,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    October 29, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the undersigned, CONDUIT PHARMACEUTICALS INC., a Delaware corporation (the &ldquo;<B><I>Borrower</I></B>&rdquo;), HEREBY
PROMISES TO PAY to <FONT STYLE="text-transform: uppercase">A.G.P./Alliance Global Partners</FONT> (the &ldquo;<B><I>Lender</I></B>&rdquo;)
the principal amount of SIX HUNDRED THOUSAND DOLLARS ($600,000) or, if less, the aggregate principal amount of the Advance made by the
Lender to the Borrower pursuant to the Loan Agreement (as hereinafter defined) outstanding on the Maturity Date (as defined in the Loan
Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Borrower promises to pay interest on the principal amount of the Advance from the date of such Advance until such principal amount is
paid in full, at such interest rates, and payable at such times, as are specified in the Loan Agreement referred to below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal,
interest fees and expenses hereunder and under the Loan Agreement are payable in lawful money of the United States of America to the
Lender at 590 Madison Avenue, 28th Floor, New York, NY 10022, in same day funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Promissory Note is the Note referred to in, and is entitled to the benefits of, the Bridge Loan Agreement dated as of October 29, 2024
(as may be amended or restated from time to time, the &ldquo;<B><I>Loan Agreement</I></B>&rdquo;), between the Borrower and the Lender.
The Loan Agreement, among other things, (i) provides for the making of an advance (the &ldquo;<B><I>Advance</I></B>&rdquo;) by the Lender
to the Borrower in an aggregate principal amount not to exceed at any time outstanding the U.S. dollar amount first above mentioned,
the indebtedness of the Borrower resulting from such Advance being evidenced by this Promissory Note, and (ii) contains provisions for
acceleration of the maturity hereof upon the happening of certain stated events and also for prepayments on account of principal hereof
prior to the maturity hereof upon the terms and conditions therein specified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 211.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDUIT
    PHARMACEUTICALS INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
James Bligh </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Bligh</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Interim Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex4-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDUIT
PHARMACEUTICALS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: _______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Original
    Issuance Date: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder
    Approval Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the
&ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after the Stockholder Approval Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00
p.m. (New York City time) on the date that is the five (5) year anniversary of the Initial Exercise Date, provided that, if such date
is not a Trading Day, the date that is the immediately following Trading Day (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter,
to subscribe for and purchase from Conduit Pharmaceuticals Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______
shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of the Company&rsquo;s Common Stock. The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Common Stock
Purchase Warrant is issued pursuant to the Note Agreement (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
1. <U>Definitions. </U>In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in
this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stoc</U>k&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock, restricted stock units, options or other equity awards to employees,
consultants, contractors, advisors, officers, or directors of the Company pursuant to any stock or option plan in existence as of the
date hereof, provided that such issuances to consultants, contractors or advisors are issued as &ldquo;restricted securities&rdquo; (as
defined in Rule 144) and carry no registration rights, (b) shares of Common Stock upon the exercise or exchange of or conversion of any
Securities issued hereunder or securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding
on the date of this Warrant, provided that such securities have not been amended since the date of this Warrant to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection
with stock splits or combinations) or to extend the term of such securities, (c) securities issued pursuant to acquisitions or strategic
transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted
securities&rdquo; (as defined in Rule 144), and provided that any such issuance shall only be to a Person (or to the equity holders of
a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the
business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include
a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business
is investing in securities, (d) shares of Common Stock issued to consultants or vendors of the Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights, and (e) shares of Common
Stock issued to existing holders of the Company&rsquo;s securities in compliance with the terms of agreements entered into with, or instruments
issued to, such holders, provided that such agreements regarding such securities have not been amended since the date of this Warrant
to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other
than in connection with stock splits or combinations) or to extend the term of such securities, and provided further that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Note
Agreement</U>&rdquo; means that certain Bridge Loan Agreement between the Holder hereof and the Company, dated as of October [*], 2024,
pursuant to which the Holder agreed to issue a note in the principal aggregate amount of $600,000 to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stockholder
Approval</U>&rdquo; means such approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any
successor entity) from the stockholders of the Company with respect to the issuance of all of the Warrants and the Warrant Shares upon
the exercise thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stockholder
Approval Date</U>&rdquo; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company required to be listed pursuant to Item 601(b)(21) of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Vstock Transfer, LLC, with an address of 18 Lafayette Place, Woodmere, NY 11598, and any successor transfer agent
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible
into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price,
exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common
Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price
that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence
of specified or contingent events directly or indirectly related to the business of the Company or the market for shares of Common Stock
or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby
the Company may issue securities at a future determined price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2. <U>Exercise.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
If the Holder exercises any portion of this Warrant by cashless exercise pursuant to Section 2(c), then the Notice of Exercise shall
include the VWAP and Bid Price (each as defined below) used by the Holder in calculating the Warrant Shares to be issued pursuant to
Section 2(c) so that the Company may independently confirm the Holder&rsquo;s calculations. Within the earlier of (i) two (2) Trading
Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the
date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable
Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified
in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this
Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is
delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company may object to any Notice of Exercise that the Company reasonably determines
does not comply with the requirements set forth herein, provided that the Company must deliver any such objections within one (1) Business
Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$[*]<SUP>1</SUP></B>, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering the resale of the
Warrant Shares, or the prospectus contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant
may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled
to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
                                            =</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
                                            Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant
                                            to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered
                                            pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
                                            hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
                                            laws) on such Trading Day, or (ii) the Bid Price of the Common Stock on the principal Trading
                                            Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the
                                            Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise
                                            is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
                                            within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular
                                            trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP
                                            on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is
                                            a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
                                            2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 67.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
                                            =</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
                                            =</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
                                            with the terms of this Warrant if such exercise were by means of a cash exercise rather than
                                            a cashless exercise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;) or the OTCQX Best Market
(&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and
if prices for the Common Stock are then reported on the Pink Open Market (&ldquo;<U>Pink Market</U>&rdquo;) operated by the OTC Markets,
Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the
Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent
appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market operated by the
OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>Equal to the Nasdaq &ldquo;minimum price&rdquo; as of the date of the execution of the Note Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate or
a book-entry certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number
of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise
by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1)
Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard
Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share
Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the
Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third (3rd) Trading Day after the Warrant Share Delivery Date) for each
Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company
agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.
As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading
Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice
of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely
due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker
to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
&ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other contained herein beneficially owned
by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section
2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises
of this Warrant that are not in compliance with the Beneficial Ownership Limitation, provided this limitation of liability shall not
apply if the Holder has detrimentally relied on outstanding share information provided by the Company or the Transfer Agent. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such
determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation,
except to the extent the Holder relies on the number of outstanding shares of Common Stock that was provided by the Company. For purposes
of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer
Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall
within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder
and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective
until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply
to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3. <U>Certain Adjustments.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Subsequent Equity Sales</U>. If the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding,
shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any
offer, sale, grant, or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price
per share less than the Exercise Price then in effect (such lower price, the &ldquo;<U>Base Share Price</U>&rdquo;; and such issuances,
collectively, a &ldquo;<U>Dilutive Issuance</U>&rdquo;) (it being understood and agreed that if the holder of the Common Stock or Common
Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion,
exercise or exchange prices, or otherwise, or due to warrants, options, or rights per share that are issued in connection with such issuance,
be entitled to receive shares of Common Stock at an effective price per share that is less than the then-Exercise Price, such issuance
shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive Issuance at such effective price), then,
simultaneously with the consummation (or, if earlier, the announcement) of each Dilutive Issuance, the Exercise Price shall be reduced
and only reduced to equal the Base Share Price (subject to adjustment for reverse and forward stock splits, recapitalizations, and similar
transactions). Notwithstanding the foregoing, no adjustments shall be made, paid, or issued under this Section 3(b) in respect of an
Exempt Issuance. The Company shall notify the Holder, in writing, no later than the Trading Day following the issuance or deemed issuance
of any Common Stock or Common Stock Equivalents subject to this Section 3(b), indicating therein the applicable issuance price, or applicable
reset price, exchange price, conversion price, and other pricing terms (such notice, the &ldquo;<U>Dilutive Issuance Notice</U>&rdquo;).
If the Company enters into a Variable Rate Transaction, the Company shall be deemed to have issued Common Stock or Common Stock Equivalents
at the lowest possible conversion or exercise price at which such securities may be converted or exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of the Company&rsquo;s assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to
sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50%
of the outstanding Common Stock and greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding
shares of Common Stock and greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,
in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the
date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder
an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date
of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company&rsquo;s
control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall not have the option to require the Company
to purchase this Warrant. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black Scholes Option
Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental
Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal
to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date,
(B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day
annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental
Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option
time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination
Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds
(or such other consideration) within the later of (i) five Trading Days of the Holder&rsquo;s election and (ii) the date of consummation
of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant
and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and
substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction
and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of
shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from
and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction
Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power
of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the
same effect as if such Successor Entity had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled
to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common
Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4. <U>Transfer of Warrant.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof
and to the provisions of the Note Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, comply with the provisions of the Note Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Voluntary Adjustment By Company</U>. On or after the Stockholder Approval Date, the Company may at any time during the term of this
Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors
of the Company, with the consent of the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
5. <U>Miscellaneous.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Note Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding the fact that
the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant or the Note
Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Note Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on
the one hand, and the Holder of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDUIT
    PHARMACEUTICALS INC. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Bligh</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:
CONDUIT PHARMACEUTICALS INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]
in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c). If this box is checked, provide the following information used by the Holder to calculate the Warrant Shares
to be issued:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VWAP:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bid
    Price:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: white 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: white 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: white 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: white 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Investing Entity:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
    of Authorized Signatory of Investing Entity</I>:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    , </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: white 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: white 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ex4-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PROMISSORY NOTE (&ldquo;<B>NOTE</B>&rdquo;) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<B>SECURITIES
ACT</B>&rdquo;). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION
OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROMISSORY
NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Amount: $600,000, plus a 1%</FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">arrangement fee rolled into the principal amount</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated
    as of October 28, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
Pharmaceuticals, Inc. a Delaware corporation (the &ldquo;<B>Maker</B>&rdquo;), promises to pay to the order of Nirland Limited, a company
organized under the laws of Guernsey, or its registered assigns or successors in interest (the &ldquo;<B>Payee</B>&rdquo;), or order,
the principal sum of Six Hundred Thousand Dollars ($600,000) plus 1% arrangement fee rolled into the principal sum and interest thereon
in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made
by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from
time to time designate by written notice in accordance with the provisions of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Principal. </B>The principal balance of this Note (including the arrangement fee) shall be payable by the Maker on October 28,
2025 (the &ldquo;<B>Maturity Date</B>&rdquo;). The principal balance may be prepaid at any time without penalty or fee. Under no circumstances
shall any individual, including but not limited to any officer, director, employee or stockholder of the Maker, be obligated personally
for any obligations or liabilities of the Maker hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Interest.</B> Interest shall accrue daily on the unpaid Principal Amount at a rate of 12% per annum and shall be due and payable semi-annually
in arrears. For the purpose of calculating interest for any period for which the interest shall be payable, such interest shall be calculated
on the basis of a thirty (30) day month and a 360-day year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Events of Default.</B> The following shall constitute an event of default (&ldquo;<B>Event of Default</B>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Failure to Make Required Payments</U>. Failure by Maker to pay the principal amount due pursuant to this Note within five (5) business
days of the Maturity Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Voluntary Bankruptcy, Etc</U>. The commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization,
rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee,
trustee, custodian, sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it
of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking
of corporate action by Maker in furtherance of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Involuntary Bankruptcy, Etc</U>. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect
of Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator,
assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or ordering the
winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive
days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Delisting, Sale or Takeover, Etc.</U> If the Maker is acquired, subject of a takeover offer, or becomes suspended from or ceases to
be listed on The Nasdaq Global Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Remedies.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Upon the occurrence of an Event of Default specified in Section 4(a) hereof, Payee may, by written notice to Maker, declare this Note
to be due immediately and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder, shall
become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly
waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Upon the occurrence of an Event of Default specified in Sections 4(b) and 4(c), the unpaid principal balance of this Note, and all other
sums payable with regard to this Note, shall automatically and immediately become due and payable, in all cases without any action on
the part of Payee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Following an Event of Default and during the continuance thereof, the interest rate shall be increased to eighteen percent (18%) or to
the maximum extent permitted by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Waivers. </B>Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of
dishonor, protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted
by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting
any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale
under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and Maker agrees
that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof or any writ of execution issued hereon,
may be sold upon any such writ in whole or in part in any order desired by Payee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Unconditional Liability. </B>Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement
of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party,
and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to
by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect
to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties
hereto without notice to Maker or affecting Maker&rsquo;s liability hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Notices. </B>All notices, statements or other documents which are required or contemplated by this Note shall be made in writing and
delivered: (i) personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission
to the address designated in writing, (ii) by facsimile to the number most recently provided to such party or such other address or fax
number as may be designated in writing by such party or (iii) by electronic mail, to the electronic mail address most recently provided
to such party or such other electronic mail address as may be designated in writing by such party. Any notice or other communication
so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt
of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier
service or five (5) days after mailing if sent by mail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Construction. </B>THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF DELAWARE, WITHOUT REGARD TO CONFLICT OF LAW
PROVISIONS THEREOF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Severability. </B>Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such
prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Electronic Form. </B>This Note has initially been issued solely in electronic form. If requested by the Payee at any time, the Company
will promptly issue to the Payee an originally executed physical copy of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Amendment; Waiver</B>. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of
the Maker and the Payee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Assignment</B>. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation
of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent
shall be void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
page follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the
day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CONDUIT
PHARMACEUTICALS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Bligh</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Bligh</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    CFO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>5
<FILENAME>ex4-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDUIT
PHARMACEUTICALS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
TO SENIOR SECURED PROMISSORY NOTE AND SECURITY AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amendment to the Secured Promissory Note and Security Agreement (this &ldquo;<B>Amendment</B>&rdquo;), dated as of October 31, 2024 (the
&ldquo;<B>Amendment Effective Date</B>&rdquo;), hereby amends each of (i) the Senior Secured Promissory Note (the &ldquo;<B>Note</B>&rdquo;)
issued by Conduit Pharmaceutical Inc. (&ldquo;<B>Company</B>&rdquo;), and each subsidiary of the Company listed on the signature page
hereto (together with the Company, the &ldquo;<B>Makers</B>&rdquo; and each a &ldquo;<B>Maker</B>&rdquo;) to Nirland Limited (the &ldquo;<B>Holder</B>&rdquo;)
in the maximum aggregate principal amount of $2,650,000 dated as of August 6, 2024, and (ii) the Security Agreement (the &ldquo;<B>Security
Agreement</B>&rdquo;), dated as of August 6, 2024, by the Company in favor of the Maker. Capitalized terms not otherwise defined herein
have the meanings ascribed them in the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing below, the Makers and the Holder agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
1 of the Note is hereby amended in its entirety as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Interest;
                                            Payments; Voluntary Prepayment</U>. Interest on the unpaid principal balance of this Note
                                            shall accrue at the rate of twelve percent (12%) per annum, computed based on a calendar
                                            year and actual days elapsed, and shall be payable, at the option of the Holder, (a) monthly
                                            in arrears or (b) in a single installment at maturity. The entire unpaid principal amount
                                            then outstanding and all accrued interest hereunder shall be due and payable on the Maturity
                                            Date. Payment of principal and interest hereunder shall be made by wire transfer in United
                                            States Dollars to an account designated in writing by the Holder for that purpose. The Company
                                            may prepay all or any portion of this Note without penalty or fee at any time upon ten (10)
                                            business days&rsquo; prior written notice to the Holder. All payments of principal and interest
                                            shall be in lawful money of the United States of America or, at the request of the Holder,
                                            in shares of the Company&rsquo;s Common Stock pursuant to <U>Section 18</U>. All payments
                                            shall be applied first to accrued and unpaid interest, and thereafter to principal.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
6 and 7 of the Note are each hereby deleted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
18 of the Note is hereby added to the Note as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conversion
                                            of Note</U>. At any time after the Amendment Effective Date, this Note shall be convertible
                                            into validly issued, fully paid and non-assessable shares of Common Stock (the &ldquo;<B>Underlying
                                            Securities</B>&rdquo;), on the terms and conditions set forth in this <U>Section 18</U>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conversion
                                            Right</U>. Subject to the provisions of <U>Section 18.4</U>, at any time or times on or after
                                            the date hereof, the Holder shall be entitled to convert any portion of the outstanding and
                                            unpaid Conversion Amount (as defined below) into validly issued, fully paid and non-assessable
                                            shares of Common Stock in accordance with <U>Section 18.3</U>, at the Conversion Rate (as
                                            defined below). The Makers shall not issue any fraction of a share of Common Stock upon any
                                            conversion. If the issuance would result in the issuance of a fraction of a share of Common
                                            Stock, the Makers shall round such fraction of a share of Common Stock up to the nearest
                                            whole share. The Makers shall pay any and all transfer, stamp, issuance and similar taxes,
                                            costs and expenses (including, without limitation, fees and expenses of the Transfer Agent
                                            (as defined below)) that may be payable with respect to the issuance and delivery of Common
                                            Stock upon conversion of any Conversion Amount.</FONT></TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conversion
                                            Rate</U>. The number of shares of Common Stock issuable upon conversion of any Conversion
                                            Amount pursuant to <U>Section 18.1</U> shall be determined by dividing (x) such Conversion
                                            Amount by (y) the Conversion Price (the &ldquo;<B>Conversion Rate</B>&rdquo;).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Conversion
                                            Amount</B>&rdquo; means the two and one quarter times the sum of (x) portion of the principal
                                            to be converted, redeemed or otherwise with respect to which this determination is being
                                            made and (y) all accrued and unpaid interest with respect to such portion of the principal
                                            amount, if any.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Conversion
                                            Price</B>&rdquo; means, as of any Conversion Date or other date of determination, $0.10,
                                            subject to adjustment as provided herein.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mechanics
                                            of Conversion</U>. To convert any Conversion Amount into shares of Common Stock on any date
                                            (a &ldquo;<B>Conversion Date</B>&rdquo;), the Holder shall deliver (whether via facsimile,
                                            electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such
                                            date, a copy of an executed notice of conversion in the form attached hereto as <U>Exhibit
                                            I</U> (the &ldquo;<B>Conversion Notice</B>&rdquo;) to the Company. Within two (2) trading
                                            days following a conversion of this Note as aforesaid, the Holder shall surrender this Note
                                            to a nationally recognized overnight delivery service for delivery to the Company. On or
                                            before the first (1st) trading day following the date of receipt of a Conversion Notice,
                                            the Makers shall transmit by facsimile or electronic mail an acknowledgment of confirmation
                                            and representation as to whether such shares of Common Stock may then be resold pursuant
                                            to Rule 144 or an effective and available registration statement, of receipt of such Conversion
                                            Notice to the Holder and the Makers&rsquo; transfer agent (the &ldquo;<B>Transfer Agent</B>&rdquo;)
                                            which confirmation shall constitute an instruction to the Transfer Agent to process such
                                            Conversion Notice in accordance with the terms herein. On or before the second (2nd) trading
                                            day following the date on which the Makers have received a Conversion Notice (or such earlier
                                            date as required pursuant to the Exchange Act or other applicable law, rule or regulation
                                            for the settlement of a trade initiated on the applicable Conversion Date of such shares
                                            of Common Stock issuable pursuant to such Conversion Notice) (the &ldquo;<B>Share Delivery
                                            Deadline</B>&rdquo;), the Maker shall (1) provided that the Transfer Agent is participating
                                            in The Depository Trust Company&rsquo;s (&ldquo;<B>DTC</B>&rdquo;) Fast Automated Securities
                                            Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder
                                            shall be entitled pursuant to such conversion to the Holder&rsquo;s or its designee&rsquo;s
                                            balance account with DTC through its Deposit/Withdrawal at Custodian system or (2) if the
                                            Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program,
                                            upon the request of the Holder, issue and deliver (via reputable overnight courier) to the
                                            address as specified in the Conversion Notice, a certificate, registered in the name of the
                                            Holder or its designee, for the number of shares of Common Stock to which the Holder shall
                                            be entitled pursuant to such conversion. If this Note is physically surrendered for conversion
                                            and the outstanding Principal of this Note is greater than the Principal portion of the Conversion
                                            Amount being converted, then the Maker shall as soon as practicable and in no event later
                                            than two (2) business days after receipt of this Note and at its own expense, issue and deliver
                                            to the Holder (or its designee) a new Note representing the outstanding Principal Amount
                                            not converted. The Person (as defined below) or Persons entitled to receive the shares of
                                            Common Stock issuable upon a conversion of this Note shall be treated for all purposes as
                                            the record holder or holders of such shares of Common Stock on the Conversion Date.</FONT></TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Limitations
                                            on Conversions</U>. The Makers shall not effect the conversion of any portion of this Note,
                                            and the Holder shall not have the right to convert any portion of this Note pursuant to the
                                            terms and conditions of this Note and any such conversion shall be null and void and treated
                                            as if never made, to the extent that after giving effect to such conversion, the Holder together
                                            with the other Attribution Parties collectively would beneficially own in excess of 9.99%
                                            (the &ldquo;<B>Maximum Percentage</B>&rdquo;) of the shares of Common Stock outstanding immediately
                                            after giving effect to such conversion. For purposes of the foregoing sentence, the aggregate
                                            number of shares of Common Stock beneficially owned by the Holder and the other Attribution
                                            Parties shall include the number of shares of Common Stock held by the Holder and all other
                                            Attribution Parties <I>plus</I> the number of shares of Common Stock issuable upon conversion
                                            of this Note with respect to which the determination of such sentence is being made, but
                                            shall exclude shares of Common Stock which would be issuable upon (A) conversion of the remaining,
                                            nonconverted portion of this Note beneficially owned by the Holder or any of the other Attribution
                                            Parties and (B) exercise or conversion of the unexercised or nonconverted portion of any
                                            other securities of the Maker (including, without limitation, any convertible notes or convertible
                                            preferred stock or warrants) beneficially owned by the Holder or any other Attribution Party
                                            subject to a limitation on conversion or exercise analogous to the limitation contained in
                                            this <U>Section 18.4</U>. For purposes of this <U>Section 18.4</U>, beneficial ownership
                                            shall be calculated in accordance with Section 13(d) of the Exchange Act. For purposes of
                                            determining the number of outstanding shares of Common Stock the Holder may acquire upon
                                            the conversion of this Note without exceeding the Maximum Percentage, the Holder may rely
                                            on the number of outstanding shares of Common Stock as reflected in (x) the Company&rsquo;s
                                            most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on
                                            Form 8-K or other public filing with the SEC, as the case may be, (y) a more recent public
                                            announcement by the Company or (z) any other written notice by the Company or the Transfer
                                            Agent, if any, setting forth the number of shares of Common Stock outstanding (the &ldquo;<B>Reported
                                            Outstanding Share Number</B>&rdquo;). If the Makers receive a Conversion Notice from the
                                            Holder at a time when the actual number of outstanding shares of Common Stock is less than
                                            the Reported Outstanding Share Number, the Company shall notify the Holder in writing of
                                            the number of shares of Common Stock then outstanding and, to the extent that such Conversion
                                            Notice would otherwise cause the Holder&rsquo;s beneficial ownership, as determined pursuant
                                            to this <U>Section 18.4</U>, to exceed the Maximum Percentage, the Holder must notify the
                                            Makers of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion
                                            Notice. For any reason at any time, upon the written or oral request of the Holder, the Company
                                            shall within one (1) business day confirm orally and in writing or by electronic mail to
                                            the Holder the number of shares of Common Stock then outstanding. In any case, the number
                                            of outstanding shares of Common Stock shall be determined after giving effect to the conversion
                                            or exercise of securities of the Maker, including this Note, by the Holder and any other
                                            Attribution Party since the date as of which the Reported Outstanding Share Number was reported.
                                            In the event that the issuance of shares of Common Stock to the Holder upon conversion of
                                            this Note results in the Holder and the other Attribution Parties being deemed to beneficially
                                            own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares
                                            of Common Stock (as determined under Section 13(d) of the Exchange Act), the number of shares
                                            so issued by which the Holder&rsquo;s and the other Attribution Parties&rsquo; aggregate
                                            beneficial ownership exceeds the Maximum Percentage (the &ldquo;<B>Excess Shares</B>&rdquo;)
                                            shall be deemed null and void and shall be cancelled <I>ab initio</I>, and the Holder shall
                                            not have the power to vote or to transfer the Excess Shares. Upon delivery of a written notice
                                            to the Maker, the Holder may from time to time increase (with such increase not effective
                                            until the 61st day after delivery of such notice) or decrease the Maximum Percentage to any
                                            other percentage not in excess of 9.99% as specified in such notice; provided that (i) any
                                            such increase in the Maximum Percentage will not be effective until the 61st day after such
                                            notice is delivered to the Makers and (ii) any such increase or decrease will apply only
                                            to the Holder and the other Attribution Parties. For purposes of clarity, the shares of Common
                                            Stock issuable pursuant to the terms of this Note in excess of the Maximum Percentage shall
                                            not be deemed to be beneficially owned by the Holder for any purpose including for purposes
                                            of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. No prior inability to convert this
                                            Note pursuant to this paragraph shall have any effect on the applicability of the provisions
                                            of this paragraph with respect to any subsequent determination of convertibility. The provisions
                                            of this paragraph shall be construed and implemented in a manner otherwise than in strict
                                            conformity with the terms of this <U>Section 18.4</U> to the extent necessary to correct
                                            this paragraph (or any portion of this paragraph) which may be defective or inconsistent
                                            with the intended beneficial ownership limitation contained in this 18.4 or to make changes
                                            or supplements necessary or desirable to properly give effect to such limitation. The limitation
                                            contained in this paragraph may not be waived and shall apply to a successor holder of this
                                            Note.</FONT></TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the Note and this Amendment:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control
with, such Person, it being understood for purposes of this definition that &ldquo;control&rdquo; of a Person means the power directly
or indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct
or cause the direction of the management and policies of such Person whether by contract or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Attribution
Parties</B>&rdquo; means, collectively, the following Persons and entities: (i) any investment vehicle, including, any funds, feeder
funds or managed accounts, currently, or from time to time after the date of the issuance of the Note or the Amendment Effective Date,
directly or indirectly managed or advised by the Holder&rsquo;s investment manager or any of its Affiliates or principals, (ii) any direct
or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person or entity acting or who could be deemed to be acting as
a Group together with the Holder or any of the foregoing and (iv) any other Persons or entities whose beneficial ownership of the Company&rsquo;s
Common Stock would or could be aggregated with the Holder&rsquo;s and the other Attribution Parties for purposes of Section 13(d) of
the Exchange Act. For clarity, the purpose of the foregoing definition is to subject collectively the Holder and all other Attribution
Parties to the Maximum Percentage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Group</B>&rdquo;
means a &ldquo;group&rdquo; as that term is used in Section 13(d) of the Exchange Act and as defined in Rule 13d-5 thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Person</B>&rdquo;
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity or a government or any department or agency thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
19 of the Note is hereby added to the Note as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>New
                                            Resale Registration Rights</U>. As expeditiously as possible, and in no event later than
                                            7 days, after the Amendment Effective Date, the Company shall file a registration statement
                                            on Form S-3 (or, in the event that the Company is not eligible to file a registration statement
                                            on Form S-3, a registration statement on Form S-1) (the &ldquo;<B>New Resale Registration
                                            Statement</B>&rdquo;) covering the resale by the Holder of the Underlying Securities on a
                                            delayed or continuous basis and shall use its commercially reasonable efforts to have such
                                            New Resale Registration Statement declared effective as soon as practicable after the filing
                                            thereof. The Company shall maintain the effectiveness of the New Resale Registration Statement
                                            or a replacement registration statement, including filing any amendments, supplements or
                                            new registration statements as may be necessary to allow the Holder to sell the Underlying
                                            Securities until the Holder is able to sell such shares without registration under Rule 144
                                            (or any successor provision or rule) under the Securities Act of 1933, as amended (the &ldquo;<B>Securities
                                            Act</B>&rdquo;) (but with no volume or other restrictions or limitations, including as to
                                            manner or timing of sale).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
20 of the Note is hereby added to the Note as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
                                            and Warranties of Holder</U>. The Holder hereby represents and warrants to the Maker as of
                                            the Amendment Effective Date and as of each Conversion Date as follows:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Power
                                            and Authority</U>. The Holder has the full power, authority and/or capacity to enter into
                                            this Amendment and its agreement to be bound by the provisions hereof constitutes its valid
                                            and legally binding obligation, enforceable in accordance with its terms.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Purchase
                                            Entirely for Own Account</U>. This Note has, and the Underlying Securities issued upon a
                                            conversion of this Note have, been purchased by the Holder for its own account, not as a
                                            nominee or agent and not with a view to the resale or distribution of any part thereof. The
                                            Holder has no present intention of selling, granting any participation in, or otherwise distributing
                                            the same. The Holder does not have any contract, undertaking, agreement or arrangement with
                                            any party to sell, transfer or grant participation to any party with respect to the Underlying
                                            Securities.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Disclosure
                                            of Information</U>. The Holder received all of the information it requested in connection
                                            with its purchase of the Underlying Securities. The Holder has had an opportunity to ask
                                            questions of, and receive answers from, the Company and to consult its own legal, tax, and
                                            other advisors, regarding the information provided and the terms and conditions of the offering
                                            of the Underlying Securities.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investment
                                            Experience</U>. The Holder can bear the economic risk of its investment and has the knowledge
                                            and experience in financial or business matters to, and is capable of, evaluating the merits
                                            and risks of the investment in the Underlying Securities.</FONT></TD></TR>
</TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Restricted
                                            Securities</U>. The Holder understands that the Underlying Securities are characterized as
                                            &ldquo;restricted securities&rdquo; under the federal securities laws inasmuch as they are
                                            being acquired from the Company in a transaction not involving a public offering, and that
                                            under such laws and applicable regulations such securities may be resold without registration
                                            under the Securities Act, only in certain limited circumstances.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accredited
                                            Investor</U>. The Holder is an accredited investor as such term is defined in the rules promulgated
                                            pursuant to the Securities Act. The Holder has been advised that this Note and the Underlying
                                            Securities have not been registered under the Securities Act, or any state securities laws
                                            and, therefore, cannot be resold unless they are registered under the Securities Act and
                                            applicable state securities laws or unless an exemption from such registration requirements
                                            is available. The Holder is purchasing this Note and the securities to be acquired by the
                                            Holder hereunder for its own account for investment, not as a nominee or agent, and not with
                                            a view to, or for resale in connection with, the distribution thereof, and the Holder has
                                            no present intention of selling, granting any participation in, or otherwise distributing
                                            the same. The Holder has such knowledge and experience in financial and business matters
                                            that the Holder is capable of evaluating the merits and risks of such investment, is able
                                            to incur a complete loss of such investment without impairing the Holder&rsquo;s financial
                                            condition and is able to bear the economic risk of such investment for an indefinite period
                                            of time.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
                                            General Solicitation</U>. Neither the Holder, nor any of its officers, directors, employees,
                                            agents, stockholders, or partners has either directly or indirectly, including through a
                                            broker or finder (1) engaged in any general solicitation of the Note, this Amendment, or
                                            the Underlying Securities, or (2) published any advertisement in connection with the offer
                                            and sale of the Note, this Amendment, or the Underlying Securities.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Security Agreement shall be terminated in its entirety upon full repayment of the Note and all other Secured Obligations (as defined
in the Note).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amendment is limited precisely as written and shall not (a) constitute a consent under or waiver or modification of any other term or
condition of the Note, or (b) prejudice or otherwise affect any right or privilege which Holder now has or may have in the future under
the Note. Except as expressly amended and modified hereby, the Note shall continue in full force and effect in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amendment shall be governed by and construed in accordance with the laws of the State of Delaware without regard to principles of choice
of law or conflict of law. EACH PARTY HERETO WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING
OUT OF THIS AMENDMENT OR THE NOTE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>[Signature
Page Follows]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDUIT
PHARMACEUTICALS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
the Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  James Bligh</I></FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Bligh</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim CFO</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDUIT
UK MANAGEMENT LTD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
a subsidiary of the Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  James Bligh</I></FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Bligh</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>AGREED
AND ACKNOWLEDGED</I>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NIRLAND
LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
the Holder</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Stefano Grace</I></FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stefano Grace</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Representative</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Amendment to Senior Secured Promissory Note of Conduit Pharmaceuticals Inc.]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right"><B><U>Exhibit
I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERSION
NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is made to the Senior Secured Promissory Note (as amended, the &ldquo;<B>Note</B>&rdquo;) issued by Conduit Pharmaceutical Inc. (&ldquo;<B>Company</B>&rdquo;),
and each subsidiary of the Company listed on the signature page thereto (together with the Company, the &ldquo;<B>Makers</B>&rdquo; and
each a &ldquo;<B>Maker</B>&rdquo;) to Nirland Limited (the &ldquo;<B>Holder</B>&rdquo;) in the maximum aggregate principal amount of
$2,650,000 dated as of August 6, 2024. In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion
Amount (as defined in the Note) of the Note indicated below into shares of Common Stock, $0.0001 par value per share (the &ldquo;<B>Common
Stock</B>&rdquo;), of the Company, as of the date specified below. Capitalized terms not defined herein shall have the meaning as set
forth in the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Conversion: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%">&nbsp;</TD>
    </TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate principal to be converted:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%">&nbsp;</TD>
    </TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
    accrued and unpaid with respect to such portion of the aggregate principal and such aggregate interest to be converted:</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 60%"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGGREGATE
    CONVERSION AMOUNT<BR>
    TO BE CONVERTED:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
    confirm the following information: </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
    Price:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of shares of Common Stock to be issued:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
issue the Common Stock into which the Note is being converted to Holder, or for its benefit,&nbsp;as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check
here if requesting delivery as a certificate to the following name and to the following address:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    to:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check
here if requesting delivery by Deposit/Withdrawal at Custodian as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
    Participant:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
    Number:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account
    Number:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
_____________ __, ____</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Registered Holder</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
ID:__________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail
Address: _____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BRIDGE
LOAN AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated
as of October 29, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
Pharmaceuticals Inc., a Delaware corporation (the &ldquo;<B><I>Borrower</I></B>&rdquo;), and A.G.P./Alliance Global Partners (the &ldquo;<B><I>Lender</I></B>&rdquo;)
agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article
I </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>AMOUNTS
AND TERMS OF THE ADVANCES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
1.01. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Advances.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Lender agrees, on the terms and conditions hereinafter set forth, to make an advance (the &ldquo;<B><I>Advance</I></B>&rdquo;) to the
Borrower, into the account of the Borrower at the Lender, on the date hereof in an amount not to exceed $600,000.00 (the &ldquo;<B><I>Commitment</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
1.02. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making the Advance.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Advance shall be made on the date hereof, subject to the conditions below, upon receipt by the Lender of written notice (the &ldquo;<B><I>Advance
Notice</I></B>&rdquo;), given by the Borrower to the Lender on the date hereof. Not later than 11:00 A.M. (New York City time) on the
date hereof and upon fulfillment of the applicable conditions set forth in Article II, the Lender will make such Advance available to
the Borrower in same day funds in the account of the Borrower at the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Advance Notice shall be irrevocable and binding on the Borrower. The Borrower shall indemnify the Lender against any loss or reasonable
and documented out of pocket cost or expense incurred by the Lender as a result of any failure to fulfill on or before the date specified
in the Advance Notice for the Advance, the applicable conditions set forth in Article II, including, without limitation, any loss, cost
or expense incurred by reason of the liquidation or reemployment of deposits or other funds acquired by the Lender to fund the Advance
when the Advance, as a result of such failure, is not made on such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
1.03. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant. </FONT></I></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
partial consideration for the Advance, the Company agrees to issue the Lender a warrant to purchase shares of the Borrower&rsquo;s common
stock in an amount equal to 50% of the sum of the Commitment divided by the closing price of the Borrower&rsquo;s common stock as of
the date of this Bridge Loan Agreement, in the form annexed hereto as Exhibit B (the &ldquo;<B><I>Warrant</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
1.04. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Borrower shall repay the aggregate unpaid principal amount of the Advance in accordance with a promissory note of the Borrower, in substantially
the form of Exhibit A hereto (the &ldquo;<B><I>Note</I></B>&rdquo;), evidencing the indebtedness resulting from the Advance and delivered
to the Lender pursuant to Article II.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
1.05. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Borrower shall pay interest on the unpaid principal amount of the Advance from the date of such Advance until such principal amount shall
be paid in full, at a rate equal at all times to 4.21% per annum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
1.06. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Borrower shall have the right prior to the Maturity Date to prepay, plus any accrued but unpaid interest thereon, any principal amount
of the Advance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
1.07. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Definitions.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ldquo;<B><I>Business Day</I></B>&rdquo; means a day of the year on which banks are not required or authorized to close in New York City.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&ldquo;<B><I>Maturity Date</I></B>&rdquo; means December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 11.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
1.08. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments and Computations.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Borrower shall repay all of the outstanding balance of the Advance hereunder and under the Note, as well as any accrued and unpaid interest
and fees not later than 11:00 A.M. (New York City time) on the Maturity Date in U.S. dollars to the Lender at its address referred to
in Section 6.03 in same day funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Borrower hereby authorizes the Lender, if and to the extent payment is not made when due hereunder or under the Note, to charge from
time to time against any or all of the Borrower&rsquo;s accounts with the Lender any amount so due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) All
computations of interest shall be made by the Lender on the basis of a year of 360 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article
II </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CONDITIONS
OF LENDING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
2.01. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condition Precedent to Initial Advance.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligation of the Lender to make the Advance is subject to the condition precedent that the Lender shall have received on or before the
day of such Advance the following, each dated such day, in form and substance reasonably satisfactory to the Lender:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Note.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Certified
copies of the resolutions of the Board of Directors of the Borrower approving this Agreement and the Note, and of all documents evidencing
other necessary corporate action and governmental approvals, if any, with respect to this Agreement and the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) A
certificate of the Chief Executive Officer of the Borrower certifying (1) that each of the representations and warranties contained in
Section 3.01 hereof are true in all material respects (without duplication of materiality) and shall be true in all material respects
(without duplication of materiality) on the date of the Advance (or such earlier date, if so specified); (2) that no event has occurred
and is continuing, or would result from such Advance or from the application of the proceeds therefrom, which constitutes an Event of
Default (as defined in Section 5.01 hereof) or would constitute an Event of Default but for the requirement that notice be given or time
elapse or both; and (3) the names and true signatures of the officers of the Borrower authorized to sign this Agreement and the Note
and the other documents to be delivered hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) An
opinion of Thompson Hine LLP, counsel for the Borrower, in form and substance reasonably satisfactory to the Lender with respect to such
customary matters as the Lender may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) The
Advance Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) Receipt
of such other approvals or documents as the Lender may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) A
duly executed Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article
III </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>REPRESENTATIONS
AND WARRANTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
3.01. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representations and Warranties of
the Borrower.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Borrower represents and warrants as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Borrower is a corporation duly incorporated, validly existing and in good standing under the laws of the jurisdiction indicated at the
beginning of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
execution, delivery and performance by the Borrower of this Agreement and the Note are within the Borrower&rsquo;s corporate powers,
have been duly authorized by all necessary corporate action, and do not contravene (i) the Borrower&rsquo;s certificate of incorporation
or by-laws or (ii) law or any contractual restriction binding on or affecting the Borrower, except, in the case of this clause (ii),
to the extent it could not reasonably be expected to have a material adverse change on the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) No
authorization or approval or other action by, and no notice to or filing with, any governmental authority or regulatory body is required
for the due execution, delivery and performance by the Borrower of this Agreement or the Note, except for those that have otherwise been
obtained or made on or prior to the date hereof and which remain in full force and effect on the date that the Borrower receives the
initial Advance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) This
Agreement is, and the Note when delivered hereunder will be, legal, valid and binding obligations of the Borrower enforceable against
the Borrower in accordance with their respective terms, subject to bankruptcy, insolvency or other laws of general application relating
to the enforcement of creditors&rsquo; rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) The
consolidated financial statements of the Borrower included or incorporated by reference in the Company&rsquo;s Registration Statement
on Form S-3 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;<B><I>SEC</I></B>&rdquo;)
on October 24, 2024 and the Prospectus included therein (the &ldquo;<B><I>Prospectus</I></B>&rdquo;), together with the related notes
and schedules, present fairly, in all material respects, the consolidated financial position of the Borrower and its subsidiaries as
of the dates indicated and the consolidated statement of operations, consolidated statement of cash flows and consolidated statement
of stockholders&rsquo; equity (deficit) of the Borrower for the periods specified, except that such unaudited financial statements are
subject to normal year-end adjustments and lack footnotes required by GAAP, and have been prepared in compliance in all material respects
with the requirements of the Securities Act of 1933, as amended, and Exchange Act of 1934, as amended, as applicable, and in conformity
with generally accepted accounting principles (&ldquo;<B><I>GAAP</I></B>&rdquo;) in the United States as in effect as of the time of
filing applied on a consistent basis (except for such adjustments to accounting standards and practices as are noted therein) during
the periods involved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) There
is no pending or, to the knowledge of the Borrower, threatened action or proceeding affecting the Borrower or any of its subsidiaries
before any court, governmental agency or arbitrator, which may materially adversely affect the financial condition or operations of the
Borrower or any subsidiary or which purports to affect the legality, validity or enforceability of this Agreement or the Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) The
Borrower is not engaged in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning
of Regulation U issued by the Board of Governors of the Federal Reserve System), and no proceeds of any Advance will be used to purchase
or carry any margin stock or to extend credit to others for the purpose of purchasing or carrying any margin stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article
IV </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>COVENANTS
OF THE BORROWER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
4.01. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Affirmative Covenants.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
long as the Note shall remain unpaid or the Lender shall have any Commitment hereunder, the Borrower will, unless the Lender shall otherwise
consent in writing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <I>Use
of Proceeds</I>. Only use the proceeds from the Advance for working capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <I>Compliance
with Laws, Etc</I>. Comply, and cause each of its subsidiaries to comply, in all material respects with all applicable laws, rules, regulations
and orders, such compliance to include, without limitation, paying before the same become delinquent all taxes, assessments and governmental
charges imposed upon it or upon its property except to the extent contested in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <I>Reporting
Requirements</I>. Furnish to the Lender such information respecting the condition or operations, financial or otherwise, of the Borrower
or any of its subsidiaries as the Lender may from time to time reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <I>Stockholder
Approval</I>. The Borrower shall hold an annual or special meeting of stockholders on or prior to the date that is ninety (90) days following
the issuance date of the Warrant for the purpose of obtaining the approval of the Borrower&rsquo;s stockholders as may be required under
Nasdaq rules to permit the exercise of the Warrant (the &ldquo;<B><I>Stockholder Approval</I></B>&rdquo;), with the recommendation of
the Borrower&rsquo;s Board of Directors that such proposals are approved, and the Borrower shall solicit proxies from its stockholders
in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders
shall vote their proxies in favor of such proposals. If the Borrower does not obtain Stockholder Approval at the first meeting, the Borrower
shall call a meeting every ninety (90) days thereafter to seek Stockholder Approval until the Stockholder Approval is obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <I>Sales
Agreement Use of Proceeds</I>. The Borrower covenants and agrees that any and all proceeds generated from the sale if its securities
pursuant to the terms of the Sales Agreement with the Lender dated October 23, 2024 (the &ldquo;<B><I>Sales Agreement</I></B>&rdquo;),
shall be used to repay the Commitment, plus all accrued and unpaid interest, until such amounts are repaid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <I>Waiver
of Side Letter Condition</I>. Reference is made to that certain side letter executed by and between the Lender and the Borrower, dated
September 22, 2023 (the &ldquo;<B><I>Side Letter</I></B>&rdquo;). Pursuant to the terms of the Side Letter, the Lender and Borrower agreed
that 25% of the net proceeds of any Capital Raise (as defined in the Side Letter) would be paid to the Lender until the full Deferred
Amount (as defined in the Side Letter) has been paid (the &ldquo;<B><I>Capital Repayment Condition</I></B>&rdquo;). The Lender and Borrower
hereby covenant and agree to waive the Capital Repayment Condition until such time as the Commitment, plus all accrued and unpaid interest,
are repaid to the Lender in full. After such repayment, the Capital Repayment Condition shall continue to remain in effect until the
Deferred Amount (as defined in the Side Letter) is repaid in full, however the Capital Repayment Condition shall not be paid from proceeds
raised from the Sales Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
4.02. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Negative Covenants.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
long as the Note shall remain unpaid or the Lender shall have any Commitment hereunder, the Borrower will not, without the written consent
of the Lender:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <I>Liens,
Etc</I>. Create or suffer to exist, or permit any of its subsidiaries to create or suffer to exist, any lien, security interest or other
charge or encumbrance, or any other type of preferential arrangement, upon or with respect to any of its properties, whether now owned
or hereafter acquired, or assign, or permit any of its subsidiaries to assign, any right to receive income, in each case to secure or
provide for the payment of any Debt, except for Permitted Liens. &ldquo;<B><I>Permitted Liens</I></B>&rdquo; means (i) liens for taxes
not yet due and payable, for less than $100,000 in the aggregate, or which are being contested in good faith by appropriate proceedings
diligently pursued, provided that provision for the payment of all such taxes has been made on the books of such person as may be required
by GAAP, consistently applied; (ii) mechanics&rsquo;, materialmen&rsquo;s, banker&rsquo;s, carriers&rsquo;, warehousemen&rsquo;s and
similar liens and encumbrances arising in the ordinary course of business and securing obligations of such person that are not overdue
for a period of more than 60 days, for less than $100,000 in the aggregate, or are being contested in good faith by appropriate proceedings
diligently pursued, provided that in the case of any such contest (1) any proceedings commenced for the enforcement of such liens and
encumbrances shall have been duly suspended; and (2) such provision for the payment of such liens and encumbrances has been made on the
books of such person as may be required by GAAP, consistently applied; (iii) liens arising in connection with worker&rsquo;s compensation,
unemployment insurance, old age pensions and social security benefits and similar statutory obligations which are not overdue, for less
than $100,000 in the aggregate, or are being contested in good faith by appropriate proceedings diligently pursued, provided that in
the case of any such contest (1) any proceedings commenced for the enforcement of such liens shall have been duly suspended; and (2)
such provision for the payment of such liens has been made on the books of such person as may be required by GAAP, consistently applied;
(iv) liens incurred in the ordinary course of business to secure the performance of statutory obligations arising in connection with
progress payments or advance payments due under contracts with the United States government or any agency thereof entered into in the
ordinary course of business; (v) liens incurred or deposits made in the ordinary course of business to secure the performance of statutory
obligations, bids, leases, fee and expense arrangements with trustees and fiscal agents and other similar obligations (exclusive of obligations
incurred in connection with the borrowing of money, any lease-purchase arrangements or the payment of the deferred purchase price of
property), provided that full provision for the payment of all such obligations set forth in clauses (iv) and (v) has been made on the
books of such person as may be required by GAAP, consistently applied; (vi) (1) liens arising in connection with capital leases (and
attaching only to the property being leased and the proceeds thereof), (2) liens that constitute purchase money security interests on
any property securing debt incurred for the purpose of financing all or any part of the cost of acquiring such property, provided that
any such lien attaches to such property within ninety (90) days of the acquisition thereof and attaches solely to the property so acquired
and the proceeds thereof, and (3) any lien existing on any property or asset prior to the acquisition thereof by the Borrower or any
subsidiary of the Borrower or existing on any property or asset of any person that becomes a subsidiary of the Borrower after the date
of this Agreement prior to the time such person becomes a subsidiary of the Borrower, provided that such lien is not created in contemplation
of or in connection with such acquisition or such person becoming a subsidiary of the Borrower, as the case may be, and extensions, renewals
and replacements thereof that do not increase the outstanding principal amount thereof except by the amount of any interest, premiums
or penalties required to be paid plus fees and expenses associated therewith; (vii) attachments, appeal bonds, judgments and other similar
liens arising in connection with court or legal proceedings, which do not result in an Event of Default, provided the execution or other
enforcement of such liens is effectively stayed and the claims secured thereby are being actively contested in good faith and by appropriate
proceedings; (viii) survey exceptions, easements, zoning and other statutory restrictions, rights of way, restrictions, land use or similar
laws and regulations affecting real property, minor defects or irregularities in title and other similar liens not interfering in any
material respect with the ordinary conduct of the business of the Borrower; (ix) deposits to secure the performance of bids, trade contracts,
leases and other obligations of a like nature, in each case, in the ordinary course of business; (x) customary rights of set-off, revocation,
refund or chargeback under deposit agreements or under the Uniform Commercial Code or common law of banks or other financial institutions
where the Borrower or any of its subsidiaries maintains deposits in the ordinary course of business; (xi) any interest or title of a
lessor, sublessor, licensor or sublicensor under any lease or license permitted hereunder and any leases, subleases, licenses or sublicenses
granted by the Borrower or any of its subsidiaries to third parties in the ordinary course of business and not interfering in any material
respect with the business of the Borrower or such subsidiary; (xii) purported liens evidenced by the filing of precautionary UCC financing
statements relating solely to operating leases of personal property entered into in the ordinary course of business; (xiii) other liens;
provided that aggregate amount of all obligations of the Borrower and its subsidiaries secured by such liens does not exceed $100,000
at any time outstanding and so long as such liens do not attach to accounts receivable or inventory of the Borrower; and (xiv) liens
incurred in connection with the restructuring or refinancing of any Debt as described in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <I>Debt</I>.
Create or suffer to exist, or permit any of its subsidiaries to create or suffer to exist, any Debt other than as described in the Registration
Statement and the Prospectus, including any filings with the SEC made by Borrower that are incorporated by reference therein, prior to
the date hereof and other Permitted Debt; provided that the Borrower shall be permitted to restructure or refinance any Debt described
in the Registration Statement and the Prospectus (provided that such restructured or refinanced Debt (A) is not for a greater principal
amount than the existing Debt, (B) does not purport to restrict the repayment of indebtedness under this Agreement and the Note, and
(C) no Event of Default shall have occurred and be continuing hereunder). &ldquo;<B><I>Debt</I></B>&rdquo; means (i) indebtedness for
borrowed money, (ii) obligations evidenced by bonds, debentures, notes or other similar instruments, (iii) obligations to pay the deferred
purchase price of property or services, (iv) obligations as lessee under leases which shall have been or should be, in accordance with
generally accepted accounting principles, recorded as capital leases, (v) obligations under direct or indirect guaranties in respect
of, and obligations (contingent or otherwise) to purchase or otherwise acquire, or otherwise to assure a creditor against loss in respect
of, indebtedness or obligations of others of the kinds referred to in clause (i) through (iv) above, and (vi) liabilities in respect
of unfunded vested benefits under plans covered by Title IV of ERISA. &ldquo;<B><I>Permitted Debt</I></B>&rdquo; means (i) indebtedness
arising hereunder; (ii) current unsecured trade payables and accrued liabilities arising in the ordinary course of the Borrower&rsquo;s
business (including, without limitation, obligations under operating leases); (iii) purchase money indebtedness and capital leases incurred
in connection with the acquisition of fixed assets in an aggregate amount not exceeding $50,000 at any one time outstanding; (iv) indebtedness
of a subsidiary acquired after the date of this Agreement or an entity merged into or consolidated with the Borrower or any subsidiary
of the Borrower after the date of this Agreement and indebtedness assumed in connection with the acquisition of assets, which indebtedness,
in each case, exists at the time of such acquisition, merger or consolidation and is not created in contemplation of such event and where
such acquisition, merger or consolidation is permitted by this Agreement; (v) indebtedness in respect of netting services, overdraft
protection and otherwise in connection with deposit accounts or similar accounts incurred in the ordinary course of business, provided
such debt is extinguished within five (5) days of its incurrence; (vi) indebtedness incurred in the ordinary course of business in connection
with the financing of insurance premiums of the Borrower or any of its subsidiaries; (vii) indebtedness arising from agreements of the
Borrower providing for indemnification, adjustment of purchase price or acquisition price or similar obligations (including earn-outs),
in each case, incurred or assumed in connection with the acquisition contemplated on the date hereof; and (viii) other indebtedness of
Borrower in an aggregate amount not in excess of $50,000 in the aggregate at any time outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <I>Dividends,
Etc</I>. Declare or make any dividend payment or other distribution of assets, properties, cash, rights, obligations or securities on
account of any shares of any class of capital stock of the Borrower, or purchase, redeem or otherwise acquire for value (or permit any
of its subsidiaries to do so) any shares of any class of capital stock of the Borrower or any warrants, rights or options to acquire
any such shares, now or hereafter outstanding, except that the Borrower may (i) declare and make any dividend payment or other distribution
payable in common stock of the Borrower, and (ii) purchase, redeem or otherwise acquire shares of its common stock or warrants, rights
or options to acquire any such shares with the proceeds received from the substantially concurrent issue of new shares of its common
stock, <I>provided,</I> that, immediately after giving effect to such proposed action, no Event of Default or event which, with the giving
of notice or lapse of time, or both, would constitute an Event of Default would exist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <I>Mergers,
Etc</I>. Merge or consolidate with or into, or convey, transfer, lease or otherwise dispose of (whether in one transaction or in a series
of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to any person or entity, or permit
any of its subsidiaries to do so, except for Permitted Dispositions. &ldquo;<B><I>Permitted Dispositions</I></B>&rdquo; means (i) sales
of inventory in the ordinary course of its business, (ii) disposition of (1) surplus, obsolete, worn out, replaced, no longer used or
useful, unmerchantable, or unsalable equipment in the ordinary course of business and (2) assets of Borrower to the extent the market
value of the property so disposed of does not exceed $100,000 during any single fiscal year, (iii) abandonment, lapse or other dispositions
of intellectual property that is, in the reasonable good faith judgment of the Borrower or its subsidiary, either no longer economically
practicable or commercially desirable to maintain or no longer necessary for the conduct of the business of the Borrower or any of its
subsidiaries, (iv) dispositions of cash or cash equivalents, in each case, in a manner not prohibited by the other terms of this Agreement,
(v) sales, transfers and other dispositions of accounts receivable (or notes accepted to evidence same) in connection with the compromise,
settlement or collection thereof in the ordinary course of business, (vi) the lease, assignment, license or sub-license or sub-lease
of any real or personal property in the ordinary course of business to the extent the same does not materially interfere with the business
of the Borrower, (vii) the license or sublicense of intellectual property, (viii) the granting of Permitted Liens, (ix) any involuntary
loss, damage or destruction of property; and (x) any involuntary condemnation, seizure or taking, by exercise of the power of eminent
domain or otherwise, or confiscation or requisition of use of property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article
V </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EVENTS
OF DEFAULT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
5.01. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Events of Default.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the following events (&ldquo;<B><I>Events of Default</I></B>&rdquo;) shall occur and be continuing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Borrower shall fail to pay any principal of, or interest on, the Note when the same becomes due and payable; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Any
representation or warranty made by the Borrower herein or by the Borrower (or any of its officers) in connection with this Agreement
shall prove to have been incorrect in any material respect when made; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
Borrower shall fail to perform or observe any term, covenant or agreement contained in this Agreement if such failure shall remain unremedied
for five (5) Business Days after written notice thereof shall have been given to the Borrower by the Lender; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The
Borrower or any of its subsidiaries shall generally not pay its debts as such debts become due, or shall admit in writing its inability
to pay its debts generally, or shall make a general assignment for the benefit of creditors; or any proceeding shall be instituted by
or against the Borrower or any of its subsidiaries seeking to adjudicate it a bankrupt or insolvent, or seeking liquidation, winding
up, reorganization, arrangement, adjustment, protection, relief, or composition of it or its debts under any law relating to bankruptcy,
insolvency or reorganization or relief of debtors, or seeking the entry of an order for relief or the appointment of a receiver, trustee,
custodian or other similar official for it or for any substantial part of its property and, in the case of any such proceeding instituted
against it (but not instituted by it), either such proceeding shall remain undismissed or unstayed for a period of 30 days, or any of
the actions sought in such proceeding (including, without limitation, the entry of an order for relief against, or the appointment of
a receiver, trustee, custodian or other similar official for, it or for any substantial part of its property) shall occur; or the Borrower
or any of its subsidiaries shall take any corporate action to authorize any of the actions set forth above in this subsection (d); then,
and in any such event, the Lender (i) may, by notice to the Borrower, declare its obligation to make the Advance to be terminated, whereupon
the same shall forthwith terminate, and (ii) may, by notice to the Borrower, declare the Note, all interest thereon and all other amounts
payable under this Agreement to be forthwith due and payable, whereupon the Note, all such interest and all such amounts shall become
and be forthwith due and payable, without presentment, demand, protest, or further notice of any kind, all of which are hereby expressly
waived by the Borrower; <I>provided, however,</I> that in the event of an actual or deemed entry of an order for relief with respect
to the Borrower or any of its subsidiaries under the Federal Bankruptcy Code, (a) the obligation of the Lender to make Advances shall
automatically be terminated and (b) the Advances, the Note, all such interest and all such amounts shall automatically become and be
due and payable, without presentment, demand, protest or any notice of any kind, all of which are hereby expressly waived by the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Article
VI </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
6.01. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination of Certain Payment Obligations.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Fee Letter Agreement, effective September 22, 2023, between the Borrower and the Lender (the &ldquo;Letter Agreement&rdquo;) provides
that the Borrower must pay to the Lender 25% of all net proceeds received in any Capital Raise, as defined in the Letter Agreement (the
&ldquo;Payment Obligation&rdquo;). The Payment Obligation is terminated immediately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
6.02. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments, Etc.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
amendment or waiver of any provision of this Agreement or the Note, nor consent to any departure by the Borrower therefrom, shall in
any event be effective unless the same shall be in writing and signed by the Lender, and then such waiver or consent shall be effective
only in the specific instance and for the specific purpose for which given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
6.03. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices, Etc.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices and other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement
shall be in writing, unless otherwise specified, and shall be delivered: if to the Borrower, at its address at 4995 Murphy Canyon Road,
Suite 300, San Diego, CA 92123, Attention: David Tapolczay; and if to the Lender, at its address at 590 Madison Avenue, 28th Floor, New
York, NY 10022, Attention: Thomas J Higgins, Managing Director (thiggins@allianceg.com); or, as to each party, at such other address
as shall be designated by such party in a written notice to the other party. Each such notice or other communication shall be deemed
given (i) when delivered personally, by email or by verifiable facsimile transmission (with an original to follow) on or before 4:30
p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii) on the next
Business Day after timely delivery to a nationally-recognized overnight courier and (iii) on the Business Day actually received if deposited
in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
6.04. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Waiver; Remedies.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
failure on the part of the Lender to exercise, and no delay in exercising, any right hereunder or under the Note shall operate as a waiver
thereof; nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or the exercise of
any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
6.05. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs, Expenses and Taxes.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Borrower agrees to pay promptly after demand all reasonable and documented costs and expenses in connection with the preparation, execution,
delivery, administration, modification and amendment of this Agreement, the Note and the other documents to be delivered hereunder, including,
without limitation, plus disbursements for searches, recordings and similar expenses for counsel for the Lender with respect to the negotiation
and delivery of this Agreement and the Note, in all cases in an amount not to exceed $25,000. The Borrower further agrees to pay promptly
after demand all reasonable and documented costs and expenses, if any (including reasonable outside counsel fees and expenses), in connection
with the enforcement (whether through negotiations, legal proceedings or otherwise) of this Agreement, the Note and the other documents
to be delivered hereunder, including, without limitation, reasonable outside counsel fees and expenses in connection with the enforcement
of rights under this Section 6.05. In addition, the Borrower shall pay any and all stamp and other taxes payable or determined to be
payable in connection with the execution and delivery of this Agreement, the Note and the other documents to be delivered hereunder,
and agrees to save the Lender harmless from and against any and all liabilities with respect to or resulting from any delay in paying
or omission to pay such taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
6.06. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of Set-off.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the occurrence and during the continuance of any Event of Default the Lender is hereby authorized at any time and from time to time,
to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or
final, but excluding balances held or assets in respect of payroll accounts, employee benefit accounts, trust accounts, withholding accounts
and other similar fiduciary accounts to the extent such funds are necessary to pay payroll, employee benefits and other similar payments
accrued and/or payable in the ordinary course of business) at any time held and other indebtedness at any time owing by the Lender to
or for the credit or the account of the Borrower against any and all of the obligations of the Borrower now or hereafter existing under
this Agreement and the Note, whether or not the Lender shall have made any demand under this Agreement or the Note and although such
obligations may be unmatured. The Lender agrees promptly to notify the Borrower after any such set-off and application, <I>provided</I>
that the failure to give such notice shall not affect the validity of such set-off and application. The rights of the Lender under this
Section are in addition to other rights and remedies (including, without limitation, other rights of set-off) which the Lender may have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
6.07. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Binding Effect.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be binding upon and inure to the benefit of the Borrower and the Lender and their respective successors and assigns,
except that the Borrower shall not have the right to assign its rights hereunder or any interest herein without the prior written consent
of the Lender. This Agreement and the Note may not be assigned or transferred by the Lender to any person other than (a) an affiliate
of the Lender or (b) so long as no Event of Default is then continuing, any other person (other than a natural person) in the business
of making loans and other extensions of credit with the prior written consent of the Borrower. The Lender may pledge this Agreement and
the Note and grant security interests herein and therein to any financing source of the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Section
6.08. </I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing Law.</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement and the Note shall be governed by, and construed in accordance with, the laws of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF,</B> the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized,
as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDUIT
    PHARMACEUTICALS INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Bligh</I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> James Bligh</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> Interim Chief Financial Officer</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A.G.P./ALLIANCE
    GLOBAL PARTNERS</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Thomas J. Higgins</I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas J. Higgins</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Managing Director</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cdt-20241028.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCOabP9z5Z8GekhvWB6bUnazysq4I6JJyEGQES2EbMJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:CDT="http://conduitpharma.com/20241028" elementFormDefault="qualified" targetNamespace="http://conduitpharma.com/20241028">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://conduitpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cdt-20241028_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cdt-20241028_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cdt-20241028_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="CDT_CommonStock0.0001ParValuePerShareMember" name="CommonStock0.0001ParValuePerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" name="RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cdt-20241028_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://conduitpharma.com/role/Cover" xlink:href="cdt-20241028.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241028.xsd#CDT_CommonStock0.0001ParValuePerShareMember" xlink:label="loc_CDTCommonStock0.0001ParValuePerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTCommonStock0.0001ParValuePerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241028.xsd#CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:label="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cdt-20241028_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241028.xsd#CDT_CommonStock0.0001ParValuePerShareMember" xlink:label="CDT_CommonStock0.0001ParValuePerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommonStock0.0001ParValuePerShareMember" xlink:to="CDT_CommonStock0.0001ParValuePerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CommonStock0.0001ParValuePerShareMember_lbl" xml:lang="en-US">Common Stock, $0.0001 par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20241028.xsd#CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:label="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:to="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_lbl" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cdt-20241028_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://conduitpharma.com/role/Cover" xlink:href="cdt-20241028.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241028.xsd#CDT_CommonStock0.0001ParValuePerShareMember" xlink:label="loc_CDTCommonStock0.0001ParValuePerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTCommonStock0.0001ParValuePerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20241028.xsd#CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:label="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45942524151360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 28,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Conduit
Pharmaceuticals Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001896212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-3272543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4995
    Murphy Canyon Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San
    Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">471-8536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CDT_CommonStock0.0001ParValuePerShareMember', window );">Common Stock, $0.0001 par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable
    Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDTTW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CDT_CommonStock0.0001ParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CDT_CommonStock0.0001ParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJM:%&@0F%W,*I"H<G/;\EZCA! TBD:Y@YPM'@]#M>'8Q_I-BJDH'IQW_'D*
M1"PPNP]"N[<@+/P@@HBM(X4/UYN'#)Y !](4#9>X6W'%KTB1FQ2O9S83EHGT
MI3WF4LN@:/31]X]Z7NUH2<2?G=M5J>)TD?F1N4TK5<$LYO?_$-"W(:BJ(Z>K
MV1Y+A!; )3)_H(Y1JG+8H>O6_HND06CW(FF_.O)RQX<WPA4VPV)8HI)W-$ [
MT)L3N<V-55EQ"K90UJJDN(Q 8'5V#?#[I5+VY<8=K)7GHJ-_ 5!+ P04
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MYH%A63[O@Z+N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ YH%A69E<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #F@6%9% TI
M.A$%   C%0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ YH%A6>#T.HFJ @  , P   T
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;72YX;6Q02P4&      D "0 ^ @  H10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cdt-20241028.xsd</File>
    <File>cdt-20241028_def.xml</File>
    <File>cdt-20241028_lab.xml</File>
    <File>cdt-20241028_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "CDT",
   "nsuri": "http://conduitpharma.com/20241028",
   "dts": {
    "schema": {
     "local": [
      "cdt-20241028.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "cdt-20241028_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cdt-20241028_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdt-20241028_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://conduitpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-10-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-10-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "auth_ref": []
    },
    "CDT_CommonStock0.0001ParValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241028",
     "localname": "CommonStock0.0001ParValuePerShareMember",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, $0.0001 par value per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20241028",
     "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001493152-24-043330-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-043330-xbrl.zip
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M""WC=*BS7[+E+2_&&Y[,6:/PR*!#QD/]<9,I*9I@&G;[%!O;;+L_%G6J1B]
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MI5Z*J@F@N7A'K$@"?1:)()F*Z?OEU4U7_!??K#;QO^8X)7S+_P%02P,$%
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MU-<(%HSO^\),R<B%;]>@]'HME>FU9G;3;J/S-AV?#LQ+#6!^8(O,W<'5#__
M_5T NA4(0)\3K8>S<2R#Q]Z:0>*0+_+?&(Z\BOUA@1640Y=N9428<$>CR+9B
M87!UK9.(%"G9A>)K(Y&?&=].S+DHBJ1(FVDW[3EQ1%2:XXRH&IM3*?U H^GS
M"?0 N2D-+EP6@_VA_XWHN_M0AOT<-;D>\W+A>* A-5F7.5(_$SOQB_4="1:?
M%W+_QMV:JH!I:W(OU5#0U+7A[,#[7F9$1XH%YK-.I_FZ[0OD!9H%=H$KU"YP
M,?Q_M_.<.>/,9KD34V/QA//8 ABL;Q4K]T0HBU7.8Q2L/=-^:'VXYV1>S/7$
M! BV@TJV4!86VENJ \66%E )X2-+[#/.>: +1"*-$ ]TSFS:9%W9:_ /&8XB
MV /^68.(5S92*'I")(0_T*54)1$XM@2"?U4)\$4BD7C_D1 54\4W$.0Y8R#U
MUY6@[I"*-2LQ$RO-+"@(^;PU$/V/E4#O$HO$?KR@G-LK^T2 ^GV1/9#_3Y7@
M[Q9<@0C</=G)@%$##\)!$6 <?JY<''*RD4)A$GTF0R-# 8*0,P;B?U,)_ ZI
MJ.#O1 C%OC<%)U05HGZB$XGY/=,!X5N/[LU[11>Y#UPO,(>RQ\UF2_6B\O\W
M)0I,_\ 8RAXWP2W1>F'R_42I(V>\ X[;&LH>-[4M4WMA^'<B9O'&KNWZF#@N
M1!NSO!44-FXZZU*' CF[F"%BNW;-!_K4$@H;-XOUJ40!WC<.*\('(J3KW^G&
M1SQG"D6.F[UZ=:(P'RD6$;49LZ!\/,G;0JGCYJQ^I2C8)V0]"(W;;,:V"T/+
MZ3N+0(. F[""=*/$8B "J9;RX*IU7R;F"-WT9>@=]DL*0N."F\F>P0 E.KTP
M--ST[H]5TO'%I- <?!>K I'PZ*T(_^YY_+MP_K@9;JG>BO"_.H__%9P_;I9;
MJA>3?]^\'*J)7#ENGSN-H>QQL]P2K9CD4_^':J3D$]ONJBG#GRL!C4$5DE^_
M:M1#8#LC@/3_S!(*O@J)<+%*3. CJ6/"_\.691/18GLH_"JDQ#[%E[Z\N>T
M]KJ(:ZW4B0D4-&X67*CKTFQMJ!4E[@Y]; $EBYO:%JFZ,-CWTMZ464CAO2R<
MMX("QLU17>HN/3C;?7/:.2H<? Q>M(<[])[JN3#/SXK%Q@.[YCL1N^M!CAMX
M#E,H9]S$TJOSPLS'Z4;2F(GY!^.Y8H07 R^R@]+&32/="B^,>J2H#3DUT_=T
MQ9K=<ZN&LYEK=/;90]'C9I'EBG%#,- ZH>K<0!24@H8#-Z&$JK_T$$2#Q(R(
MFTYW.K$;R1T#4,X*"ATWF72INS#DCW+WY(#Q)II*[MY94V@(18V;.GHT7ICV
MD1_%G$],H(1Q<\9"74C#Q=TZ6-A'>+@78Q1;0DGCYI ^E6CC\QPT/L_/')]Q
M<TF7.B3(V[7SYA@;3CF;$_?^/&\!\%ZE2J#W:+[T]LATVY1]0)F*4C_NS8MB
M_@Y3*'GDK:@^G9=FGH0LIN'6I7LFB A,CK:7X;@ 4%X*&@GDO:I ]2CW'3Y3
MSG\7<B7&E&@I:+A-&7RW'IQ%H.&HPGW/$MTHL?@D>6)PJ70UK'(<%0Y3*/LJ
MW.]TZ,19@+I=Z[T_/VV?5NE#[RH!C4 5;GSZ52,MR8NI?>88>Z*W)"8[#WV!
M<)6 !J(*-T']JM$V&JB^43"7_CO_)X90[%58&%RH$87V."*<OTNT<5E[AYT3
M0RCM*JP +M2(0OLNHFINQKO?E%S%B]T>6A]U1P$H_2JL\_5JQHG"^GDK_W97
MH3<$!=;@1T94@;]3+=;348+ K@O9GO9%2)0#O\\>&H!J;&!U*[YP"(;Q@JK#
M65?JC'7?MX:CO!0T'+B),%0]SHGXX*D*WO/PD1T4?!52WB*%.!O0DBEGP3V7
MQ#N_/S*#@JY"?EN@#X7S.R(>5;*,@XU]ACBE]KZ.WA]_@ P+6 $T-E7(?,]B
M@G-%XOEYF.D3,O4PB=/O!S'^>:]+>,M!8U2%I!A" &GNI)]WS='PW>:!SJBR
MBRTF=!V_,PT]^J=2@.+00%7CF5!@'@7Q>MO*"31-/F:?%GYX5)OW2PURW[>0
M$CCYUI#6_QO[JL8*OM/DVS;H^$Z2_\%&?=]A@MOR[GBUO^RW$9EW_@)02P,$
M%     @ YH%A66>[B,.X-   /6L!  H   !E>#$P+3$N:'1M[7UI;]M8UN9W
M ?H/G*"[80.,8V>IZHK3P2BVD_*+Q YLIPJ%P7R@Q"N)'8I4<;&C^O5SMKN1
ME)?$]E@N=:,[EL3E+N>>]3GGO/GU[-/'M_W>FU\/!OOP;X#_>7-V>/;QX.V;
M9_PO_/I,?G[S[GC_C^#T[(^/!_]Y,LZSZG6PLSVO@K-DILK@2%T$)_DLRD+^
M(@Q.59&,G\"-<.OGF]ZW&\RB8I)DKP.\U/SOR=LW[X^/SMRG/1U'LR1=O+[J
M>71MF?RE^/5/WOXK&Y;SW3?/\($PW\^-D5;J6_4T2I,)C*%()M.*'_%C@W_W
M]N#;-!DF%3QE:^?-LW<=+UZ=)?K!D>X&[AJ/5%:IXC9'#ZO][N1P_\-!O_?Q
M>' 4##Z<'!Q\.C@ZXW5?S4FM]I;L1Y6*^[VH#/)Q<#RJ\J$J@N>_A,'S[><O
M5W52][DE_ZW+*ADOY,LDBQ4^?'OK59+=YI3V\BRNDZK?^SR-BEDT4G65C**T
M# ZST5881,&^2J.+J%#!*"_F>1%529X%&]54!?]*XS_K?!<.WYO#M^_RHL@O
M5/'FV>%;/'7_*NC'37A$%@>#K0];G[>>#=(TB;*1"CZD^3!*@\]1466J*#N>
M]U'!C%M/ X*:%$H%0%;C/$WSB_+UH]J-53[S\O2JB+)RG!>SUT$]GZMB%)6*
M./2@ ,I*5;]W&*PN6[YRDI^.OQR=G?9[@Z/]X.S@Y--I</P^./OU(!CL_S8X
MVCLX7=VY/T+^=]5V B,Z52-D>?W>SM;VSE:@.9)>!+KF]E;X#/C@(#Y')EEN
MF876KUS]!=>KJBG)7\Q',4'80E!#27P%)*W@6A"9*.'@.,Y*$H@C$+L)TE49
M3%6ADBP:PX]!J2IX8%%-PZ#*84Y?0=1E0<0$T2$EA52:8A)OKG 86BJ'09+Q
M=T$T&N5U5J%:AA_U%4%4T6<>N!EQ#&H<C1 N3S(:S(QNS_(*WZ*^C92*@W_\
MM+T=;F]O;VUO=XQR+Y_-DFH&R]T<Z-:CVOF_.WM\?N?L\5/T-<DF1)E"^FLF
MN9(3W(@V V*4LHU!.8W2-!@J&&.L.KA/&)3U\+] ;,+;7 XZ5& )A$";<%NA
M1BJ!:0T7#CM#9G=1)%6E,F1<R66\M-\[HBO:ALPD.8?[Y<&&;\IP](M: ]\*
MX'E!&B%[KZ; 0'=V7@.7'&Q]V@HV<,'^R(NOP5Y2P7-AS3;E$?V>RWI19-#T
MQG4Z3M(4>:GFX-%\GH+)-DR]-3&2!-FVJ-[!X6'H#O8"GL1"IJQ'4WVB@N@\
M2E)Z7I7W>]YDX5EE-,/Y+6 H65SB-]>6*FMN_\"GM#%LG$H^"O9P)D6ASG,F
M-J3)(0P%&;*0O=[V+7R*)0*^'4<]RV 6+@E&DRC)R@H>M@C2O"R#O( C')5Y
MAN\ <Q]>$N>C&@D>](R\)A*;YZ.O0-^C'.Z$&]2WN<I*&%TVJF& <>/P1Z!R
MP4/+.J6;\55CH/"Z0 +7)PJG (\:*C@TRI[A<JY&R3A!5Y90>F-IX'+WZ_![
MCB2,.ZUQ'4,XDM44)YDFH#&1KR4T:Q/2A/N])3/F9=,G,$W^K).8O36TIFHV
M3_.%9ARQFN=E4M%ZYW!](<<Y&L%M[26D=8*M<&;:[UU,5>;/O;'2Q%5DJ6&6
M)2F-FK_3C[C&:Z[PH*=T0QWPQ9WK@+]'!8REPO?XFM^MO6%0]GOS" YHE.+Y
M+1,X GR2.D\[F#=S/*-L[.%92<JR5AX+"BYXU/CKO"Y&4U@^Y(MP6)HR\U]%
MB0I'":^>S7!5RPK8G6]]J3]K&!L\Z]7V/_7]93W3?UJ#*XB3<QB^.<\C8"3(
ML.<%,J_+WQSPB\F%SWH L42Z"0[SNR*))S##'(8UP*GC^T*M$""IP( S]0U>
MCEH,#!:>I(-B[SH4,-G8M8VX4E.Z(7]X>>?\X43-(Y)S:]-P)2=XYCJN1'<L
M<$]9M9H JYD@'ZJS>93$R,FR43('=BB\49B:UM.0;X)Q4L3T"?4KX,;S(I\!
MD\Z+!>HD+49(7 SLS;("?@12(%TP_R.F!M=J+C;0G*W-S$ ][# A%3)C&*[X
M,' -AZ#79@HT7]:;\*<QC,Z; VG!*@7[LT!-U#<Y09R4M8@6JU7^';CF_WKZ
M-'B?J#1^'7R.)FH7;O^SAN7%VX*G3P7H\F;_\#<]")[1TV%>53EPJI^0?0V!
M-E1AOGN71B#T=F"J99XF,<SB;/#NXT&P=_#QX^?!_O[AT8?_/-E^0I]//P_V
M]&=Y@SQME*=I-"]A)/JO7:"]N)KBC+;_V76NST[T,V";*0BK%[G*Y_ZJIVI,
M=^QW05@X[..]SB[@V3X"?D[P_W!6\"^L3L="#<&:^/J4K:'7P9Q65Q8/1D,K
M]W=:&8?2GB&I,77=]:EZ\O_U].J%X1'P?V\3N_0(&-,-=9]7=Z[['"*!J_*1
MJCZ/3G?N5G90U4ED([5G[9K*CM$<M*7F.7;AAB3EKUH/HE?W>T,5T(L2<C6G
M(3IPHZ# I['-B9]AC!7-$S2.EUO/=_X9S-'&S;)Z]G=0.U9X2C=D6#_=.</Z
M7&AK;0UW6,T)=G&P:73.[B^"4R.SR4V@[%-4U05&NQ A2NXP(H$PF*=U2;YN
M,->*&EU6=:7YGF&'%07$Q"G>9&+]GL\.U\SH04_IALSHYSMG1GM@740@^?;5
M.,DX:+-F2C>8H#]HW.#.*=\%EJ#?\]'(=9F04V4_6C2\,,%, ;V!4H,Q;.$7
M"Q51Z/YBFH!N-(RRKW!!H2A>52B)B $+B^IJFA?PZA@9%_K2R;_D1?'OC.FL
M#B^Y55*]U3'>0P"]08F>N.LFQ7TU4C-,CWBQP^D1=RVW]/1W=K9V7M$BKPAA
M/7PA]>^[UYA%72:G,(8>:\8)K$75:D[0(.$Z0Q[XEPBIO*XP'D%XFV&4DD7?
M,/]1.:XYX(R ,89N3 FKPNB,"P7/BWPUFR_UU&S&W8PQFIU]#WBMH>2#B/RR
M=;H5Q.CP+<H&9"ZJ @2B1'%<<!ADK C2@N SN%-.5_#3UO:+-OYLK>(_\"D9
M2)DA;R32X<+J4J6'.T\8["@D D-#$(.X"#P($:&/XMHE>M#0FC2/:MH4%H-=
M8_T>4BD]'/]UP6>HW=FSUD)$"+ZQY "B2[UXDL2%EN-XUA3YP*>T,=H,!NCK
M'#G",Z#\!G$R^%CD!I*8&=PP*A.Z*1+C81R\^&D;^=*:)3V8A+7K9R0^YI3$
MO>.C_<.SP^.CTW[O^'WP\> (([6K.]]'R)1N8F0\OX\TQ#V-6@X^8T(%3AJE
MYB%ZQ:)TG7NSTA,D=2P?PCLCAH>/&U!O2@GQ,%3ETNP;=-]K IEZV1YN+("R
M<L[1B=9 V6.:RZ(5J&2L%>;W$RA>10(5CS5J?$$(+<&8QAJJ-5(V=V !AD*5
ME.-H5"'*RS,Y_E8U ]HO-T@>BLZ(7^RF,V<8D./D-0"J[=OU*(%]W.^=B4+?
MU*UN=?>V?J;%N7H+GVYO/5]A->L>+3^,J$CZS"B?)Q;L#GIVGM9&]6:;*RIB
M_+"? +N 4]M"QF->39&?,WH2>))!G;/):!T=&3T'N8_.'2H=Z"4P/\IXR8 I
ME64$W$&7-L$\-F)J^(1)?JZ*#&_& ".].4I+L5 7G*J#\Y@;MKAT2&N3X(%/
MZ0;(TA>[P?&<"/<UOD#TLMW@MRBMX>?G:^"I!Z]TEU(OXFYPMIC#^P=%-$Q&
MN\%1-%.\T$<Y+M]S#V^I[\)?;AO ^MG?'Q%>%OGX $"@Z]/\?1X>D#@L?$:1
M!?CO31.%\'TU MD#>NGQ&'[G_'!/T/"M"Y0T&SN;K-F2%FK$%ZB])8H&%F'(
M["7#"X4<:,<()%#H4>_WM ?[!5AN)J$;U=^BYO0$RL*&HX.FE0B4,MC0J:!Q
M3<FD6E775R;58I.57^VMNO1Y_=ZU'NCFKS>""QN@N)/ZK:(B36"1\"(2AV5N
M\V0W=X.-Y[)B60Y2%V7A%'/(1IRJRK&%A!<IR6K2\.'1%WF=QCIYE'",GDD
M5QAPHZ37NL8+2&<L1%(R0 BO#"6:CPE\55+5E<)M"@[..0.VW]M7XPC?M0&#
MBQ'Q0=MEX@VO[&YMVO'9I[D/"_2S$+*D<P0%.# SII%4'H"=XDH">!T0<K^G
MB$^3802:R2[MZL:+37I*%LT4TQ=M;PGG"&,K5I/*F80[E"4/K( W7J:B\+;0
M TDYLHH3W Q#-NDGUM^^UFH>^)0V8N"#P(! \\[DK)Q-\]D<T\1_!7H/0+'
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MS1.RFS#17.)5#EB$5:UU^.FA3PFQ1=S@7+QCXGOZ&%W 70?5B F$?A?$PHC
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MH6-Z@5@L9V1/@\H ]QZ<')X.ED)?KG]N,'. W7WF$ JJ@TYKAO!^XTTCKXO
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M4R%*%VYW%K,,V[T-&\7IOX.R" =X-6EU HEOL@#+CI8S>ZJX(B4#':RHB(F
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M'.P.@P]'\-?! 8[E_=$I?O3-\>%[&<3Q@'[SX6!O6'OX8/<4G[K]R[-G83"
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MK]K.*XZ5[1M;YRIH.E9LU+FO(\5A'WB)R.99ND3O&E=#9<1ZO,:TXZSBV(W
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M><UD'(WK:3T9I@V&!LG/+5P%!'EJN N:-/8=7P6(L?#O@N!6KP)''TX7A;J
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MD(9)V .:GT6V,HIQ&K"\8&,A1B"'H4T7F-GB6,47#Y/261JWF(_AEP5>D0S
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M@=@:Y'%MT6,)[5Q1YO?B57#(?>9>XIM.&%+X*OB('2SA[^LJ0*<*<+#Q176
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MQ]J+[<G.X=[O>,">O#U]_^[7_P]02P,$%     @ YH%A6;>=Q)>]$@  56,
M  D   !E>#0M,RYH=&WM76MO&[>V_2Y _X$WN"EL0'[%26X;^QB0)3G6@2/Y
M2'*#X.)^H&8HB<T\5,Z,'-U??];>)$<CVTE/&K>J4P5(['F0W"37?F].3B]'
M[Z[.ZK73RTZSC9^"_IR.NJ.KSMGI@?V)IP?N\>EYO_U!#$<?KCK_>#9)D_R-
M.#J<YV*D8Y6)GKH5@S262</>:(BA,GKR# W1]/IKVYV(6)JI3MX(>K7\>R)R
M]2G?DY&>XM$O19;KR?+9V>E%OS>J#K$WD;&.EF]^:Q!^-]/_KRQ-S\Y^2,;9
M_.3T@#K$(ES_D>0;/9WECTG\Z?E9Y]-,CW5>K[W</SX].#_[<V;RQ#?B#R!_
M=-D=UFO7@_Z[[G#8'WP0O?ZH(W9^B,)?B_0$&T77M$$_&+ZS*RZ;0WI)G'<Z
M/3'HO.T.1YU!IRUN>NW.0(PN.V+8:=T,NJ-N9RB:K9'H7XBCGXZ/&P(-F^\Z
M>*TM=NB]U2"K%O4:FE3'VQ=$HB6+AN9AFZU_W71IT(O^0'1[/W>&(W2,H7I7
M'T2SUQ;OFA\<D6+8OVIC&0;-WO"B,Z!&:-,<#KMO>_B]VV.2F^?#3J_5(5KM
ME ;-4;??J]=P@YX/.L/F58=^'71PZ_-S1=<]T;_N]M":>FOU;WK#SA4Z: [[
MO>8YZ!NBZ^$%WJ;EQOB8PSML4*M_W6':AS?GPU&3J!GU>8Q6_]UUL_>A7AM=
M-K'K-ZW+-2*%71[<LXNR_V3!^&?R4J"27)E'EFHK/JK7/.,\V=W ?/R&W)_%
M"% &,CM75\/K9JO;>_N/9X?/^/JZV6[[ZZ^>Z:T.\QF]>OC\1(Q3$RJS%Z11
M).<9Z/*_/6,CX'0T^/H!%LKD.I"17[<\G3]S)L7IJ/V["7YU^!P+5FZMW; ]
M=/Z&-LI=CM,\3V/<><Q=NC8Z"?1<1J(9IP61_=^O#P\;A_@KYE&1"2F.GJ_M
MGOB]?S8R/VF,3*8J!KN*B5+"  ,J%#K)4Y'/E)B7\Y<\_\I481NVOV5O[]E
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M0,[@N0RX6,X^XLZY[ >J886-9JCLK*;CW:PA=N2NF,)@38*YGR2@$V4<@S@
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MF/\M"EU^N>X@_98>MP6FX'"*\6!*"+-SB&"1H7B(N=<>8,@_!--,N8V 9JJ
MSB5^:A-8>;<]P_1MF3?ZB\.Y%NI+%NJEY9@4K\!EN:_[WYM'BGFA/;Z%_LZX
M+)=YW(QI7:UI?LDT7UFJ(?,*I/\C=V74>V?'MUO:>R?]18VG7/95C:?7V=UX
MLZCXRNS9U'4%-[-8K#TF,F8Q(QQW,$F,5X7!G0Q?S3_5XK8"+&\7TXIA8H=V
M#_?$!IAV3"VBL(ZJBWJ (I$P4X@H+CNM*9LC&SA]6SL\F3!3B/'&*J\D.,!*
M@IC^+C;6I'926K!0[:13W&2;?N?K-K6BR[72M%9SZ286HINP>M@*' CUOCKD
M'U7$-]%;X)VKAU)-:U<KG=].O;%-)[0#GHNHUQ<)F[OYO?G+S>_56KV5)KUZ
M)S9?<.'!.R$%25 *NL<V? *P!S*.:4RV0<;I!M_]=<!IPE: @'N2 Z_S5/F.
ML+A_ASM@.)8V1NH?JC TTKT.X,,;DSV [H96JDYU&3,HJ<RON41(\2Y5A9J*
M)<YP*/.VGG,;=++U[!>)J1GNR@2Y:]2:@"MJ*T>SUL6@V#G8O*V76TM(+LE%
M5"6<!6SAI)+7(,W?O:'F26SP=I?2!"Z=B=R@\UU;X^>ZU[F4YMU(PL#J($X[
M\/6]@ZE#\!5'D/MFLY,]=[LSM'*;W)&:9EOXLRO"V1?!$6;3)D+I%;/^VC2T
M&;G'Z)]?C77X%Q.G\Y'-5T%QWO1Y[H#G"[A73<W,D\GH7;+-0)0 @ ,^MWXR
M%Q,S"'+ S#U2_L[]1+@$^ELKW>GF>!V<]5@VE<F2&I8QQN..!J'$.P=!JN@O
MJ+Q&1+EK,N[9IU[KJHVUD11:+W6OG#I,7:1B)P;50<NN5^'5@7\D8G&NQR;7
M793$=1<)XEY-0**N)B ;: UBO0DIL^,Z)_RW[,XGPB4S]]0Y1^Z;J@*2$!=^
MRHF!#MP6DY=>3PEAT K*29<U3:5X)/U0,]K X!?4M'5F6NB2\VY$N\G' 6M6
M9,N(%C#["L-H U4>>(=^6,KBV009V^"'KUT<,?J '_;1B/;,=#:2&:#[UV8F
MDP"3,SPW?=7V(Y4B90LS+&P44F#@6F!YBR/2W)CG"9X"A@3QC1Q3,1-:\5!P
M-V.LP&!>I,\'/$X"F.S@2#@#_%5*%#>E1*&T2=P+OUW#WK>&6$&$)R,;2'7A
MQ)!8*#%D!EMO]V>Z#F+N57!O[AW &: H9/[V!K:<O@\&=ZZ(N%520:<)W\B:
M88G#YF('*18%<F#K"7Z8I>BY^U&95#:3+TZ16E(,9Z4%T:L$/#$,/%D?ERP\
MJH:U4_@#Y 3.MQX)32@Y0 *BW@#ZQ<%N@! MIWT+[BVOC(!M>X:&*?6\P@+0
MMU?O8%($A)C@4 @ P&-W-"I2]&%$ 'A>S#J!W4_<=RRB<>^HIB!JR\'<O:A.
M4[Q+3]P Y\8HBD5>Q0&DQ0/30721/F/<AP<(? A82/8@0X1%R\<N94" *G3L
MJ]@0-863R4&)S6>!!=K%9B9W8/@X*=0++R/BH;OFI3=2ZG4]!@2CNV$<KDGG
M*1?B*A>*H2"LF6V 00W:C46IZ3-X[M<PKD8"S8AM#5.%2<"SNEZQMIBK+5'0
MNBI2$+FO/R!9:HJ2)29>+H:2FICNE6/YE)3]FPMGJNN@+I!C@(D5A_$?!W3,
M>120K#)9W &>RPJ9OR:^-R(^_[6 ]G2M)R9>D/QP&5TR @L31-!$Y%%HC'39
M88QHS+:1""8V9,#0;#-[R)@^I]]$C'4ZR H/N,4SL 692!(GDUP"!+(U@)$\
M^3BI:@._ 2WZ^QQ2:RK*T< "X>K"+A6X64,UC>B@ Z 3- RQN<Q@8(5T@+MB
M,C-MBMR"04@J"U6B,$LVU3;C&LYD*DR]9PV:#(;@^&+?(. =FX=N>3$WE[6&
M A875X(17DTH&1L6$+?/["##@3G).U;YAEK'T;0UJRQ[.S2&<34NC)%L>,P=
MU[#CB+7TNRN^U0KZ30F^%:I:LF-A8-^C%4\&@^'NF":TT\; '5V*=;S<Q;<H
MMS:Z>-P0ECQ*-80M:J1;WE5'U7!WP&2:BM? @W( \/&*-MM!8PKL),&0T(!R
MN\1%(=RARTI];B.!3=&!N1)6C/!.N.DQ4K'> XSZ5RY5(##9&@()CJ@H:,5M
M%&Z@V?2.>6I'!_T!*VCVA6KAD1^NA,(LZ'H4'C=SCL3[Y0*@D0EH0Q@>1 O,
M@ EJR;$$GW&6#+/4'\Y KZ)6=M6],]740/K%N-G !3RJ"$Y^L#+N6[ $VO:4
M:ZQUQ.EM@/<'EHJ>&_YDP]-;U+#EZ3T_ :F$VZ8;P?9>T]A<TY3,FJ8H4";'
MK% %HWA&RU2H4_&!$#)^L!XU8+,2-U]CW'Q-1-FN%NNK27P-MH,(,H$4APX3
MO!7(0X=[N-.@AFO@%E*DSHT"<1LOC*6P#G4TMV0?_QI<2%_NC!T&W)!!95AB
M52;@<\@]V0>3!<"XHB];])OB:*(8KN $N0U/^)?0H(\EP;BXU>@0H(QV1OR0
M! D#M\.G9B"*6Z\M)> -<$^S*[0.V(9>D,D'LN9@ &DRDL\=T94IHMQRFAZH
M]\.S3N1YZC;R[XRRBCTO,#,8Z\4L#%%W$PTWS;!FS)!$#*M>.EWXBFQ&B<E0
M2+W)=!58C^>JP=.+J>P\"\O.VDBUN$D6$)Z"C[Q4S*FBC/D_G7WM?B^D$F[Y
M"H\*,)OP66 \@41(BH=4\P0FWH7;*!&;#=Y'J0WHSC(TQ:\,9H"8'YGPBW\I
ML5G@"L"ME6T!7ACUHN2O@JL9)AU,HF>XGEP?+(],7S,;Y'Q&O^1G_/381 SW
MW9PDG]@,+6V $,4[SU;S[PX 9;OL,*^?(329#FB0#?53S$U:FKC)/#AJ6KX"
MMF$JP&AO9*B8[PSXC ;NJ^#:F@S558(K9((5=-6!QH0;/@:M@>ZS&]T2,4_<
M$.)W'@[%_L*$\;%E8L;#\X',U2:F.U&NJ"=!@ U5_03N1A\#LF$(^YB_91O<
M&_-B!#&@T9XM&!2^G?\Q;X>H",_&9!W'$ILS?&\*^4.P#O>2'#1 </\&Q0%,
MN((+Y#E)X4TDP0VKHS#7>O[U@<>-GMF8H,^;YO$OOC7H[BHD0L;B5$Y,_#_<
MCJ2V3>6>"'O41CVUC<Y]-I,">987?TGB+VX'YE.Y!- ^#V5P128L>Q&-&_BK
M86-L84+HLY!/MSX".$2#')N"#+X "@U_K>XV$QF=S/5OH0GNFZH=55CPB!#>
MS0?":8QV!+ N" M41RC@'%XF0N"]MF#?-C5)(BUTA'3J$=('3D\"M+UE6UD<
M4"BY)CJJNZDZ!J[#-24\W<P[\%$1D5;2X)<CH',^*<+/J^][%P4+:W_*I=P<
MA19>C]*:3=^03:54)D<J)O/Q:!5$JVR3@TG2_+GO;@2,?/@?>'$6<M[I)/>I
MQOV"9H\Q4$R^& 7O>'JCPBIS^DHO^QNP.%+8FL7?D,5SJ(DO=5^)Q2;?"X-5
MK@F/9GKH;\V8;\B8H>C.3/)7( J&;T/V?]B_9B/6%T8\;O,%#ESQI^XVOH@Q
MN%F%T6=)^;:K%X"(B)&YS:=1#?I 58V']H6"\$Y3Y3?HIPWIDW=VRCN(,&^_
M"V?EB>EM.%$\.^L7 1$_2@G2HV"(HB?2QAR**:O$YM[5P6-OZ&U8T^=].G8[
M$<$!F"Q0F#Q"YP;A+G6^4\//VL/P;4ML&_L616C8X-+% BT>!8F'J::)>_PN
M6#^(&AU:,TZ>-9,'%XXDQF:G3(#Q)*6!#NI\K2%B/E-5L9)\O-)"R-48R,:9
M[$X)5C66]-F!DPH1@CYJ4S=[977&1W#; (<-Y5/L%99C7?%XH=)COW^O,%=_
M29P$ % WAB8=3-#(I+8*JAYYO/0%[JMV)QJ&4?7Y-S;RZ/G<<[#^0X,ORCQ+
MN?72Y9LPU_"U6R$TSHP9QO?.!_]6_:()U64YT;W+&DL1[.*GP9?CCK=:W.K4
M5@LM\GN\%3U2>BUWCO*I[)]21&P9%@0E/1.+3+!1/IE-]6Q8?K&/(XI2@>V_
MFZ;+J]6YHB0GK4GN94A.$B2'?J)7[]WU1-=D-TMVN8]+=DNCL)R@,"]Y>D6D
M6F2)D(5I+I_*_^9B^.J)O+0@\2].7BQ.()%];HK?9.UX#&(V1R]!%!Y:FLWD
M\DY(A=.F\>?'#OL+(GE_U/$&P@<32=X;GZ^FTLMF@H;6S#FG(!5/#_%[5/RK
MJA"+4?6[%7UO0MSY/XRVYWG.+P9_Q0#*X"#S:E!U7#(J3J%6J4W)@:JYZ=HR
MMN0UJ,CW_<8)L6G7XOL%>%)5\8XRN+LHJJZINMM0,60'.<97>/3#W?7W: TT
M:5T#[8/60(O"=8$RA.]V.^L7Q1.7'D5KU@_/RJW+1JVYPKL]*[W!&"Z+$,I
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M              "  :4.  !C9'0M,C R-#$P,CA?;&%B+GAM;%!+ 0(4 Q0
M   ( .:!85F?^J4^]0@  -]J   4              "  0L;  !C9'0M,C R
M-#$P,CA?<')E+GAM;%!+ 0(4 Q0    ( .:!85EGNXC#N#0  #UK 0 *
M          "  3(D  !E>#$P+3$N:'1M4$L! A0#%     @ YH%A6?=+^A9R
M!@  W2(   D              ( !$ED  &5X-"TQ+FAT;5!+ 0(4 Q0    (
M .:!85ERFHT:R50  *8F @ )              "  :M?  !E>#0M,BYH=&U0
M2P$"% ,4    " #F@6%9MYW$E[T2  !58P  "0              @ &;M
M97@T+3,N:'1M4$L! A0#%     @ YH%A6<H5A(])*   ,44!  D
M     ( !?\<  &5X-"TT+FAT;5!+ 0(4 Q0    ( .:!85F;%D)'I1T  "W=
M   +              "  >_O  !F;W)M."UK+FAT;5!+!08     "@ * %$"
(  "]#0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CDT="http://conduitpharma.com/20241028"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cdt-20241028.xsd" xlink:type="simple"/>
    <context id="AsOf2024-10-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2024-10-28</startDate>
            <endDate>2024-10-28</endDate>
        </period>
    </context>
    <context id="From2024-10-282024-10-28_custom_CommonStock0.0001ParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:CommonStock0.0001ParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-28</startDate>
            <endDate>2024-10-28</endDate>
        </period>
    </context>
    <context id="From2024-10-282024-10-28_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-28</startDate>
            <endDate>2024-10-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-10-28" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-10-28" id="Fact000004">0001896212</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-10-28" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-10-28" id="Fact000010">2024-10-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-10-28" id="Fact000011">Conduit Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-10-28" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-10-28" id="Fact000013">001-41245</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-10-28" id="Fact000014">87-3272543</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-10-28" id="Fact000015">4995     Murphy Canyon Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-10-28" id="Fact000016">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-10-28" id="Fact000017">San     Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-10-28" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-10-28" id="Fact000019">92123</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-10-28" id="Fact000020">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-10-28" id="Fact000021">471-8536</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-10-28" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-10-28" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-10-28" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-10-28" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2024-10-282024-10-28_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000026">Common     Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-10-282024-10-28_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000027">CDT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-10-282024-10-28_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-10-282024-10-28_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member"
      id="Fact000029">Redeemable     Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-10-282024-10-28_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member"
      id="Fact000030">CDTTW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-10-282024-10-28_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member"
      id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-10-28" id="Fact000032">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2024-10-28" id="Fact000033">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
